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ABSTRACT  
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Microcontainers Leading to Targeted Delivery of Oral Vaccines 
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March 02, 2017 
Master’s Degree Program in Bioengineering  
Department of Chemistry and Bioengineering 
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Oral vaccination, one of the prominent ongoing research areas of drug delivery and immu-
nology, requires effective targeted drug delivery method as well as triggered immune 
responses. In this thesis project, polymeric microcontainers (MCs) formed on silicon 
substrate were used as drug carriers. The focus of the thesis was on the development and 
optimization of pH-sensitive and adjuvant-based polymer lids on the drug-loaded MCs in 
order to facilitate the drug release at the desired area (small intestine) and to trigger im-
mune response. In this study, the development of double-layered lids on top of the MCs 
was achieved by establishing a pH-sensitive outer lid made of Eudragit L100-55 polymer 
and an inner lid made of chitosan polymer incorporated with an adjuvant - MPLA (mono 
phosphoryl lipid A). The chitosan-MPLA lid is a novel polymeric lid which has not been 
in any literature yet for targeted oral drug delivery studies. The purpose of the outer lid 
was to protect the inner lid from dissolving in a gastric pH value (e.g. at pH 3.5); whereas, 
the adjuvant-based inner lid was needed to facilitate the drug release from the MCs in the 
small intestinal pH value (e.g. at pH 6.0) followed by triggering immune response.  
The model drug used in these studies was amorphous sodium salt of furosemide (ASSF), 
prepared in a spray dryer followed by loading the drug into the MCs using an embossing 
method. Next, different polymer solutions were spray-coated on the drug-loaded MCs to 
form single or double layer lids. To determine the most optimized lid formation, detailed 
lid morphology was analyzed using scanning electron microscope (SEM) and stylus 
profiler. The results show that both the inner and outer lids were homogenously formed 
where the inner lid had very smooth surface with an average thickness of 6.2 +/- 0.3 µm 
and the outer lid had porous texture with an average thickness of 31.4 +/- 2.8 µm. To 
investigate the pH-sensitivity of the lids, in vitro drug release experiments were performed 
in buffer media with different pH values (pH of rat’s gastric and intestinal media) using a 
micro dissolution apparatus. Finally, x-ray photoelectron spectroscopy (XPS) analysis was 
performed to detect the presence of MPLA in the inner lid.  
Both the release studies and lid morphology analysis exhibit that the optimized double-lids 
remains intact with a negligible drug release percentage at a pH value corresponding to the 
stomach, whereas it degrades and releases above 84% of the model drug in the medium 
corresponding to an intestinal pH value. Thus, the pH-sensitive and adjuvant-based dou-
ble-lids development demonstrates the future potential to be used for different vaccine 
formulations in targeted oral drug delivery in in vivo and animal studies.   
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ABBREVIATIONS AND DEFINITIONS   
µDiss Micro Dissolution  
AA Acetic Acid 
ASSF Amorphous sodium salt of furosemide 
Avg Average 
BCS Biopharmaceutical classification system 
Chi Chitosan 
CNTR Counter number of passes  
DBS Di butyl sebacate  
DC Dendritic cells 
EHT Extra high tension 
EL Eudragit L 
GI Gastro intestinal 
HCL Hydrochloric acid  
HP High pressure 
IDR Intrinsic dissolution rate 
IgA Immunoglobulin A 
IgG Immunoglobulin G 
IPA Isopropyl alcohol   
KH2PO4 Potassium phosphate monobasic 
LC-MS Liquid chromatography-mass spectrometry 
LMW Low molecular weight 
LPS Lipopolysachharide 
Mag Magnification 
MC Microcontainer 
M-cells Microfold cells 
MiliQ water Ultrapure water 
MPLA Mono phosphoryl lipid A 
NaOH Sodium hydro oxide  
PBS Phosphate buffered saline  
PEG Polyethylene glycol 
PLGA Poly (D,L-lactide-co-glycolide) 
SD Standard deviation  
SE2 In chamber secondary electron 
SEM Supra scanning electron microscope 
Si Silicon 
SU-8 A negative photoresist containing 8-epoxy groups 
TEC Tri ethyl citrate 
VP Variable pressure 
VPSE Variable pressure secondary electron 
w/v Weight in relation to total volume  
w/w Weight in relation to total weight 
WD Working distance 
XPS X-ray electron spectroscopy  
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1. INTRODUCTION 
This chapter briefly introduces the thesis project and its significance. It also presents the 
project overview, objectives and the scopes of the thesis.  
1.1 Vaccination and its Significance  
Vaccines often consist of biological material (e.g. virus, or bacteria) (1) stimulating the 
immune system to produce adaptive immunity towards certain infections or pathogens 
(2,3). A vaccine formulation typically consists of an antigen and an adjuvant, but some-
times it has additional preservatives, stabilizers or antibiotics added to its composition 
to protect the formulation from either bacterial contamination, or from losing its effec-
tiveness during storage (4). Vaccination is the most effective and widely used methods 
of preventing infectious diseases worldwide. Its significant contribution to public health 
and disease prevention has made it an enormous focus of study (3).  
There are different types of vaccines such as inactive vaccine, attenuated vaccine, virus-
like particle vaccine and subunit vaccine (5). In addition, the DNA vaccines and den-
dritic cell-based vaccines are emerging new generation of vaccines (6). The vaccine 
formulation can be administered in various routes, such as oral, injection, transdermal or 
intranasal. (5). However, most vaccines are injected into the body, but it would be easier 
and more beneficial if the vaccine formulation could be made suitable for oral admin-
istration.   
 
Oral vaccination is a non-invasive drug administration and  has several advantages (7). 
Delivering drugs by the oral routes is in general cost-effective, easy to administer and 
does not require any skilled person for administration. Nevertheless, there are several 
challenges in oral administration of vaccines; for example, the low pH and the presence 
of degradation enzymes in the stomach often destroy the antigen and inactivate the vac-
cine formulation. As a result, the antigen cannot generate immune response when it 
reaches the small intestinal tract at its target area (8).  
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1.2 Project Overview  
For protecting the oral vaccines from degrading in the gastric medium, one of the solu-
tions is to modify the actual drug formulation in such a way that it can survive the ex-
treme gastric environment (9). Another possible solution can be to encapsulate the for-
mulated vaccines into micro-fabricated drug delivery devices or microcontainers that 
are made of biocompatible and biodegradable polymeric materials (10,11) which would 
be capable of targeted drug release (7,12).  The IDUN Drug research group at DTU 
Nanotech is working on a project for developing microcontainers as an oral drug deliv-
ery system for vaccines (13), The research group has already developed particulates 
intended for oral vaccine delivery, and now is trying to come up with potential ap-
proaches to ensure the effectiveness of targeted oral drug delivery using the microcon-
tainers. The microcontainers aim to protect the vaccine formulation through the gastric 
medium or stomach, and then release the formulation into the small intestine near the 
M-cells (micro-fold cells). Therefore, the microcontainers require suitable lid coated 
over them with desired properties (e.g. pH sensitivity and drug release capacity) to en-
sure targeted drug delivery to specific cells along the intestinal lining. The thesis is a 
part of this project to develop polymeric lids on microcontainers.   
1.3   Aim of the Thesis  
This thesis project is aimed to develop double-layered polymeric lids on microcontain-
ers (MCs) containing specific drug formulation. The inner layer consisted of chitosan 
incorporated with an adjuvant – MPLA (Monophosphoryl Lipid A) for pre-activation of 
the immune cells. The outer layer consisted of a pH sensitive polymer, Eudragit L100-
55 to provide protection to the inner lid as well as the drug from degrading in the gastric 
medium. In addition, the outer lid contained such properties that it would get dissolved 
inside the small intestine while making the inner lid exposed. On the other hand, the 
purpose of the inner polymeric lid was to carry the incorporated adjuvant to the small 
intestinal immune cells and let the drug to be released at the targeted site.  The objective 
of incorporating the adjuvant was to provide a targeted drug delivery to the small intes-
tinal immune cells by triggering the specific cells.  Fig. 1.1 illustrates the placement of 
the double lids on the microcontainers loaded with vaccine formulation, and Fig. 1.2 
summaries the steps towards polymeric double-lids development.  
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Fig. 1.1: Placement of the polymeric double lids on top of the drug-loaded MC 
 
 
Fig. 1.2: Major steps of developing pH-sensitive and adjuvant-based polymeric double-
lids 
List of the thesis objectives: 
The objectives of the study are listed below: 
i. Successfully loading the model drug (ASSF) into the MCs 
ii. Development of MPLA-chitosan lid  
iii. Development of Eudragit L100-55 lid 
iv. Studying the lid morphology 
v. Investigating the pH sensitivity of the lids by in vitro drug release study in different 
pH media 
vi. Optimization of the double-lids development 
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1.4 Scope of the Thesis  
The entire thesis report can be divided into three main parts where, 1) Theory, 2) Labor-
atory experiments and 3) Future implications. The report is organized as below. 
Chapter 1 of the report introduces the subject matters, gives an overview of the project 
and states the project objectives. Chapter 2 discusses the thesis background and com-
monly used terms, while the Chapter 3 of this report explains the techniques used in this 
study; for example, scanning electron microscope imaging, x-ray photoelectron spec-
troscopy and micro dissolution profiling. In Chapter 4, the methodologies of different 
experiments performed during this study are illustrated. The methodology starts with 
ASSF drug formulation and loading it into microcontainers. Following the drug loading 
process, a polymer solution (chitosan) incorporated with an adjuvant (e.g. MPLA) was 
spray coated on the loaded microcontainers, which were then further spray coated with a 
pH sensitive polymer (Eudragit) to form a pH sensitive and adjuvant based double-
layered lid. After forming the polymeric double lids, in vitro drug release tests were 
performed to test the behavior of the lids in gastric medium and small intestine medium. 
However, there were some limitations to some of the experiments which are described 
in this chapter. 
In Chapter 5, the results of the drug release test, the lid thickness measurement using 
stylus profiler and the lid morphology analysis using SEM are discussed in detail. This 
chapter also includes the MPLA detection results from x-ray photoelectron spectrosco-
py (XPS). However, due to the limit of detection of the XPS, the small amount of 
MPLA incorporated into chitosan lid could not be detected. Therefore, for future studies 
other detection methods such as liquid chromatography-mass spectrometry (LC-MS) 
could be used for MPLA detection if convenient. Lastly, the report concludes with some 
future implications and potentials of this project in Chapter 6. The successful develop-
ment of the double-lids from this in vitro study needs further investigation in cell study 
and in animal studies as the next step of the thesis project.  
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2.  BACKGROUND 
This chapter discusses the basic aspects of oral drug delivery, important components of 
vaccine, and the chemical and mechanical properties of different polymers, plasticizers 
and the model drug.  
2.1 Oral Administration of Vaccines 
Oral administration of vaccines involves immunization through a mucosal route (14). 
Since pathogenic infiltrations from the mucosal tract are responsible for most of the 
infectious diseases, therefore, when vaccines are delivered to the tissues of this tract, 
they can actually mimic natural infections. Hence, vaccination to the mucosal tissues 
can provide protection during the very initial infection attack and that is why oral deliv-
ery of vaccines has become the most preferable route of administration (15). Neverthe-
less, depending on the location of the mucosal tissues, the mucosal surfaces are exposed 
to different environments such as gastric environment and mucus barrier that pose chal-
lenges towards oral vaccine formulations (7). Some of the challenges to overcome are 
the extremely low pH condition in stomach, the presence of proteolytic enzymes and 
bile salts and the low permeability of the drug in the intestinal cells (15). Nevertheless, 
comparing with the injectable vaccines, the oral vaccines are more promising and more 
efficient. Studies have shown that injectable vaccines produce insufficient specific mu-
cosal immune responses and are therefore ineffective in preventing infections at the 
sites of mucosal entry. On the contrary, both the antigenic specific systemic antibodies 
(IgG) in blood and mucosal antigen specific antibodies (IgA) can be produced by oral 
vaccines. In addition, oral vaccines are proven to be effective for both the aged and 
young M-cells (15). 
2.2 Antigen 
Antigens are molecules that can induce immune response in the host organisms by bind-
ing to the product of the immune response (16); however, some antigens are themselves 
the parts of the host organisms. Antigens can be any substrates from the environment 
including chemicals, pollens, virus and bacteria, that enter the body, or are already parts 
of the body, and they trigger the immune system to produce antibodies against the anti-
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gens (17). Therefore, each antibody is antigen specific so that the antigen binding site of 
the antibody can be bound with the specific antigen (Fig. 2.1) (18,19).  
 
Fig.  2.1: Interactions between antigen and antibody at the antigen binding site (18) 
2.3 Adjuvant 
Adjuvants are immunostimulants or immune-potentiators widely used in protein vac-
cines in order to improve the humoral, cellular and mucosal immune responses. Adju-
vants help minimizing the amount of foreign materials of vaccines (e.g. virus, or bacte-
ria), by enhancing the immune response to produce higher amount of antibodies and to 
provide longer lasting protection (20–22).  
Adjuvants can also modify the immune response in such a way that it would extend the 
presence of antigens in blood. Furthermore, adjuvants can act as stabilizing agents to 
absorb the antigen presenting cells, to activate macrophages and lymphocytes, and to 
provide support to cytokines production (4).  
2.4 MPLA 
Monophosphoryl lipid A (MPLA), is a synthetic adjuvant derived from lipopoly-
sachharide (LPS) (23) and it has been proven very effective in terms of inducing Th-1 
type immune responses to heterologous proteins in both human and animal vaccines. 
The molecular formula of MPLA is C96H184N3O22P and its molecular weight is 
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1763.469 g/mol (24,25). The suggested storage temperature for MPLA is -20ºC (24). 
The chemical structure of MPLA is presented in Fig. 2.2. 
 
Fig.  2.2: Chemical structure of the adjuvant, MPLA (Adapted from (24)) 
Studies have addressed MPLA as one of the most promising adjuvants for animal and 
human vaccines (26–30) and it has already been approved for the Hepatitis B vaccine in 
Europe (26,27). Also, it has been used for anti-cancer vaccine research in the USA (28). 
In addition to that, orally administrated nanoparticles, such as poly(D,L-lactide-co-
glycolide) or PLGA, with incorporated adjuvant MPLA (31) and model antigen OVA 
(ovalbumin) have shown potentials in both systematic and mucosal immune responses 
in mice (23). Another recent study has proven that the coating with MPLA evokes a 
strong cellular immune response and the functionalized hydroxyethyl starch nanocap-
sules with MPLA significantly enhance the uptake of nanocapsule by the dendritic cells 
(DCs) (32). MPLA functionalized microcapsules are also being tested in vivo for target-
ed drug delivery to combat infectious liver diseases with promising results (33). There-
fore, MPLA has been chosen as an adjuvant to be incorporated into the polymeric lid of 
this study, so that the adjuvant-based lid can enhance immune response at the targeted 
drug delivery site.  
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2.5  Microcontainers 
Microcontainers or MCs are micro size polymeric carriers or devices of drug for oral 
drug delivery (10,12,34). They have been previously used as oral drug delivery system, 
especially where the poorly water soluble drugs are involved, biodegradable polymeric 
MCs are used in order to improve the bioavailability of the drug (9-11). A study pub-
lished in 2016 has shown that compared to ASSF (amorphous sodium salt of furo-
semide) in capsule, ASSF in polymeric MCs has a relative bioavailability of 220% (35). 
Microcontainers vary from micro and nanoparticles. The MCs used in this study were a 
model system and they were fabricated in-house in the epoxy (30) polymer SU-8 by a 
two-step photolithography process and silicon was used as the substrate . Each small 
squared cut of silicon had an area of 12.8×12.8 mm, and it contained 25×25 = 625 mi-
crocontainers. The outer diameter of the MCs was 300 µm with an inner diameter of 
220 µm. The total height of each microcontainer was 305 µm with the actual container 
depth of 270 µm. (Fig. 2.3) 
 
 
Fig.  2.3: Supra SEM images of A. SU-8 microcontainers on silicon substrate; B. of a 
single microcontainer stating the dimensions  
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MCs are designed for unidirectional drug delivery with only one side of the microcon-
tainer open and the other side has a flat base with a walled reservoir (36). The middle 
cavity of the microcontainers is filled with drug and can then be coated with a lid to 
protect the drug from undesirable environments and to ensure targeted drug delivery (9). 
 
2.6   Furosemide 
Furosemide is a diuretic drug that prevents body from absorbing too much salt, and thus 
letting the salt to be passed through urine (37). It is a poorly soluble drug, which has 
been widely utilized in different drug dissolution studies (38). According to the Bio-
pharmaceutics Classification System (BCS) standard, furosemide falls into Class IV 
which refers to low solubility and low permeability (39). The oral bioavailability in hu-
mans is stated to be very variable from person to person and is found to be in the range 
of 43-69%. The chemical formula of furosemide is C12H11ClN2O5S and molecular mass 
is 330.75 g/mol. The chemical structure of furosemide is given below (Fig. 2.4). (40). 
 
Fig.  2.4: Chemical structure of furosemide (40) 
Furosemide is used to treat edema by reducing extra fluid in the body for the patients 
with heart failure, kidney disease and liver disease. It also can lessen the symptoms of 
shortness of breath and swelling of limbs such as arms and legs. Moreover, it can also 
treat high blood pressure, or hypertension. (37). Common side effects of furosemide 
include numbness, tingling, headache, dizziness and blurred vision (40). Therefore, it is 
important to wear safety mask and gloves during working with Furosemide in laborato-
ry.  
10 
 
2.6.1  ASSF 
ASSF or amorphous sodium salt of furosemide is formed from a sodium hydroxide con-
taining aqueous solvent (41). In this study, the ASSF utilized was prepared in house by 
spray drying pure furosemide powder and the detailed process is provided in the Mate-
rials and Methods section later in this report. The prepared ASSF has a glass transition 
temperature of 101.2 ºC and it exhibits 291 days of physical stability at 22 ºC. Studies 
have shown that storing the amorphous form of furosemide at 40 ºC and 75% relative 
humidity, converts the amorphous form into crystalline form after 2 days. The apparent 
solubility of ASSF in different gastric and intestinal stimulated media is proven to be 
much higher compared to other forms of furosemide, such as furosemide free acid and 
other amorphous forms. In addition, the ASSF demonstrates good biorelevant dissolu-
tion behaviors in micro dissolution experiments and stable conversion of salt into poly-
morph (42). Comparison studies have been done in rats using pure furosemide and 
ASSF, and the results show that ASSF is more suitable and advantageous over pure 
furosemide in terms of biorelevant dissolution, and solubility in oral drug delivery 
(32,33, 34). Thus, the promising properties of ASSF especially its high intrinsic dissolu-
tion rate (IDR) and apparent solubility in in vitro and in vivo studies for oral vaccination 
(32–36), have made ASSF to be chosen as the model drug for this study.   
2.7 Eudragit  
Eudragit polymers are derived from esters of acrylic and methacrylic acid and their 
physiochemical properties largely vary depending on their functional groups. (45). Fig. 
2.5 provides an example of different functional groups in Eudragit polymers and their 
varying behavior. Eudragit polymers are well known to be utilized as coating on oral 
solid dosage forms since 1954 (46).  
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Fig.  2.5: Different functional groups of Eudragit polymers leading varying drug re-
lease behaviors (46) 
There are many different grades of Eudragit polymers with different physical and chem-
ical properties including glass transition temperature, solubility, physical appearance 
and field of application. (46), (47). For example, the glass transition temperature of Eu-
dragit L100-55 is 110 ºC, whereas it is only 9ºC in Eudragit NE 30D (47).  Table 2.1 
represents availability, solubility and application of some widely used Eudragit poly-
mers in drug delivery studies.  
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Table 2.1: Dissolution properties of different commonly used Eudragit polymers for 
drug release (46-48) 
Eudragit Poly-
mer 
Availability Dissolution Prop-
erties 
Applications 
L 30 D-55 30% aqueous disper-
sion 
Soluble in intestinal 
fluid above pH 5.5 
Enteric coatings 
L 100-55 Powder Soluble in intestinal 
fluid above pH 5.5 
Enteric coatings 
L 100 Powder Soluble in intestinal 
fluid above pH 6 
Enteric coatings 
L 12,5 12.5% organic solu-
tion 
Soluble in intestinal 
fluid above pH 6 
Enteric coatings 
S 100 Powder Soluble in intestinal 
fluid above pH 7 
Enteric coatings 
S 12,5 12.5% organic solu-
tion 
Soluble in intestinal 
fluid above pH 7 
Enteric coatings 
FS 30 D 30% aqueous disper-
sion 
Soluble in intestinal 
fluid above pH 7 
Enteric coatings 
NE 30 D Cationic, yellow Swellable, permea-
ble 
Sustained release 
E 100 Cationic, yellow 
granules 
Soluble in gastric 
fluid up to pH 5 
Film coatings 
 
2.7.1  Eudragit L100-55  
Eudragit L100-55 is a white powder and has faint characteristic odor. It has an average 
molecular weight of 320 000 g/mol. This giant polymer contains an anionic copolymer 
based on methacrylic acid and ethyl acrylate with a ratio of 1:1 free carboxyl group: 
ester group as shown in Fig. 2.6 (49). 
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Fig.  2.6: Chemical structure of Eudragit L100-55 (49) 
Eudragit L100-55 is soluble in methanol, ethanol, isopropanol, acetone and sodium hy-
droxide and the solution gives clear to cloudy color depending on the solvent. However, 
this polymer is practically insoluble in water, petroleum ether, ethyl acetate and meth-
ylene chloride. For storage, Eudragit L100-55 should be kept away from moisture and 
in between 8-25ºC. (49).  
2.8 Plasticizer 
Plasticizers, also known as dispersants, are the chemicals that are added to polymeric 
substances to enhance their flexibility, workability and viscosity, and also in some cas-
es, to aid the polymers’ processing. Adding plasticizers to polymers lowers their modu-
lus, reduces glass transition temperature and decreases tensile strength. (50,51). Adding 
plasticizer to the polymer induces greater mobility by disturbing polymer-polymer in-
teractions in the polymer chain and establishing polymer-plasticizer interactions (52). 
There are more than 30, 000 substances that have plasticizing properties and, in 2014 
the total global plasticizers consumption was about 8.4 million metric tons (53,54). Ma-
jority of plasticizers are organic esters and the choice of plasticizer depends on the 
properties desired in the final product and its applications. Toxicity, compatibility, hy-
drophobicity or hydrophilicity, ease of mixing, stability in processing and service condi-
tion are some important criteria in choosing the convenient plasticizer (50).    
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2.8.1  TEC  
Tri ethyl citrate (TEC) is the most common plasticizer used with Eudragit polymers 
(47). It is an ester of citric acid (55), whose chemical formula is CH3COOC 
(COOCH2CH3) (CH2COOCH2CH3)2 (Fig. 2.7) and the molecular weight is 318.32 
g/mol (56).  
 
Fig.  2.7: Chemical structure of TEC (56) 
It is a colorless and odorless liquid (55). The TEC used in this study had a purity of 
99%, with the density of 1.136 g/ml at 25ºC. The boiling point of TEC is 228-
229ºC/100mmHg (lit.) and it has hydrophilic properties (56).  
2.8.2  DBS  
Di butyl sebacate (DBS) is a bio-based di butyl ester of sebacic acid (57).  It is usually 
produced from cracking of castor oil, resulting into colorless and odorless transparent 
oily DBS liquid (58).  Its chemical formula is [-(CH2)4CO2(CH2)3CH3]2 and molecular 
weight is 314.46 g/mol (59). Fig. 2.8 shows its chemical structure below.  
 
Fig.  2.8: Chemical structure of DBS (59) 
The boiling point of DBS is 178-179ºC/3 mmHg (lit.) and its density at 25ºC is 0.936 
g/ml (59). It is highly pure, cold resistance, hydrophobic and easily biodegradable plas-
ticizer (58). The water solubility of this plasticizer is only 0.04 g/L (60). DBS is soluble 
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in hexane, toluene, ethanol and acetone but insoluble in water and propylene glycol 
(59).  
2.8.3 TEC versus DBS 
Both the TEC, a hydrophilic plasticizer, and the DBS, a hydrophobic plasticizer, are 
widely utilized in Eudragit L polymers. Studies have shown previously that TEC and 
DBS, the both plasticizers affect the water absorption behavior, adhesive properties of 
Eudragit polymer coating, drug permeability and other mechanical properties including 
tensile strength, modulus of elasticity and glass transition temperature of the polymer 
coating (52,61–65). Therefore, in this study, both plasticizers were incorporated with 
EL100-55 polymer solution in separate experiments prior to lid formation to see their 
effects on the lid stability as well as the capacity of targeted drug release. In the begin-
ning of the lid development study, the TEC was chosen as the plasticizer for EL100-55 
because it is the most common plasticizer used in this polymer (66).  Due to higher wa-
ter solubility of TEC, polymer pellets incorporated with this plasticizer seem to have 
much faster drug release compared to DBS incorporation (65). TEC incorporated poly-
meric films take up water more rapidly and thus render an increase in the permeability 
of the polymer films. On the other hand, TEC was found to be rapidly leached out of 
polymeric coatings, in contrast to DBS. This phenomenon resulted in decreased me-
chanical resistances of the film as well as facilitated crack formation (63). Studies have 
shown that theophylline pellets coated with TEC has an approximate zero-order release 
rate, whereas, it is a two-phase release profile if the pellets are coated with DBS, in con-
trast (64).  Studies done both in vitro and in vivo have shown that DBS is a good choice 
as a hydrophobic plasticizer for Eudragit polymer in terms of controlled drug release 
(67). Therefore, both TEC and DBS are chosen as plasticizers to be used in this lid de-
velopment study.  
2.9 Chitosan 
Chitosan is a linear polysaccharide often obtained from the outer skeleton of shellfish 
such as shrimp, crab and lobster. (68, 69). Chitosan is derived from chitin, the second 
most significant natural polymer, upon deacetylation (Fig. 2.9).  
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Fig.  2.9: Deacetylation of chitin polymer to derive chitosan (Adapted from (69)) 
It can have varying degree of acetylation, thus different numbers of acetyl groups along 
its chain and therefore, chitosan can have varying molecular weights (68,70). Chitosan 
is biocompatible, hydrophobic, nontoxic, pseudo-natural cationic polymer with pH sen-
sitivity (68).  About its physical properties, chitosan has high surface area, porosity, 
tensile strength and conductivity (71). Moreover, its hydrated form shows good muco-
adhesive properties, so it supposes the facilitation of transmucosal absorption of, espe-
cially some polar drugs, at the intestinal epithelial cells (71,72). Chitosan has been 
widely used in immunization vaccine research and development, however it has poor 
immune response in terms of mucosal application and therefore, chitosan often requires 
an adjuvant for boosting an immune response (73).  
In this study, the chitosan was used to carry the adjuvant, MPLA to the targeted drug 
delivery site.  The chitosan used in this study, is called low molecular weight chitosan 
(LMW Chi), purchased from Sigma-Aldrich. According to the information provided by 
its manufacturer, the LMW Chi has (71) a molecular weight between 50,000-190,000 
Da, depending on its viscosity. The viscosity of this polymer is 20-300 cP and deacety-
lation percentage is 75-85%. The LMW Chi is soluble in dilute aqueous acids. (74). 
Though chitosan has its optimum solubility at pH 4.0, or even lower (71), the solubility 
of chitosan polymer largely varies depending on its different percentage weight in rela-
tion to the volume of solvent (% w/v), as well as on the type of solvent (e.g. acetic acid 
(AA), melic acid, and citric acid) (75).  In this study, 0.5% w/v of LMW Chi in 0.1M 
AA was used which has a pH value of approximately 3.4 (75).    
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3.    TECHNIQUES  
This chapter introduces and then illustrates the techniques and their usages. For exam-
ple, loading microcontainer technique, spray coating technique, lid morphology and 
analysis techniques are discussed with images.  
3.1    Spray Drying Technique 
Spray drying is a technique that transforms liquid into dry powder by atomization 
through an atomizer in a hot drying gas medium (Fig. 3.1). It is a rapid, cost effective, 
scalable and reproducible technique which is often considered as a dehydration process. 
However, spray dryer is also utilized in encapsulation process of hydrophilic and hy-
drophobic active compounds (76,77). It is a very scalable process for producing dry 
pharmaceutical powders without substantial thermal degradation and with high percent-
age yield. Spray drying is suitable even for heat sensitive substances due to its fast dry-
ing process and relatively short heat exposure. It has, thus, become a key player in pro-
ducing different inhalable drugs (77).  
 
Fig. 3.1: Schematic diagram of a spray drying process and an image of a real spray 
dryer (Adapted from (78)) 
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In Fig. 3.1, during the process of spray drying, the equipment has to be heated in the 
first step at a desired temperature. It has a two-fluid nozzle which has high cavitation 
with durable and precise reproducible capacity. The double nozzle system works for 
droplet formation and in the drying chamber, the conductive heat exchange between 
drying gas and the sample droplets takes place. The aspirator delivers the drying gas and 
the cyclone powder collector made of glass and electrically conductive layer prevents 
product losses in the cyclone, and thus particles get collected with high yield. As shown 
in Fig. 3.1, there is an outlet filter or collection vessel which collects the finest particles, 
at the end of the process (77,79).  
3.2    Powder Embossing Method  
Powder embossing method is a novel method recently introduced in order to ease and 
enhance loading efficiency of MCs with drug. Different drugs including pure drug, li-
pid-based microparticles and pure polymer have been successfully loaded into MCs 
using this method. In this method, as shown in Fig. 3.2, a shadow mask is used con-
forming to the dimensions of sample MCs to align the shadow mask on top of the sam-
ple. The shadow mask helps to load the cavities of the empty MCs precisely and pre-
vents deposition of drug between the MCs. Following the alignment, the desired powder 
drug is embossed into the MCs applying specific pressure under the bonding press 
equipment. Thus, this is an easy-going drug loading process which can simultaneously 
load many MCs in a single step. In this study, the powder embossing method was used 
to load 625 MCs at a time.  However, further research is ongoing to ensure the scalabil-
ity and reproducibility of this method in terms of homogenous loading (80). 
 
Fig. 3.2: Powder embossing method- overview of empty MCs and a shadow mask (left); 
alignment of empty sample and shadow mask (middle); loaded MCs (right, top-to-
bottom: pure drug-lipid based microparticles-pure polymer) (Adapted from (80)). 
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3.3    Spray Coating Technique  
Spray coating is a widely performed conventional coating approach for achieving micro 
and milimeter thickness of coating. This coating technique undergoes three consecutive 
steps- i) formation of microdroplets of the desired solution (e.g. Eudragit solution, and 
chitosan solution) from the spray coater through atomization; ii) deposition and 
adherence of the droplets onto the sample (e.g. drug loaded MCs) placed on the spray 
coater’s hotplate; iii) coalescence of those droplets on the substrate and formation of 
intact coating (81,82). Fig.3.3 depicts a diagram of spray coater’s configuration which 
basically consists of  a spray nozzle (e.g. accumist, micromist, impact nozzles), 
connected to a compressed air pump and a coating solution.  
 
Fig. 3.3: Schematic view of spray coating configuration (Adapted from (83)) 
The coating solution inlet fitting is connected to a syringe driver where the solution 
filled syringe is clamped on and the solution is injected into the nozzle for atomization. 
Once the sample or substrate for coating is placed on the hotplate, the spray coating 
parameters such as atomization air pressure, gun-to-surface distance, spray area, infuse 
rate and temperature, are optimized based on the solution specific coating requirements. 
The quality of coating is highly affected by the spray coating parameters and the physio-
chemical properties of the coating solution (82).    
3.4    µDissolution Technique 
The µDiss profiling is a miniaturized dissolution method that requires very small 
amount of active pharmaceutical ingredient (API) and dissolution medium (84,85), and 
therefore, is widely used in drug release or dissolution studies (86). Besides continuous 
monitoring of drug absorbance, the µDiss apparatus can measure the IDR, with the help 
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of additional mini-IDRTM disc.  Thus, the µDiss profiler has been used to evaluate dis-
solution behavior and obtain drug dissolution rate, even for poorly soluble drugs such as 
furosemide. As shown in Fig. 3.4, this versatile instrument has fiber optic UV spectros-
copy that collects the real time drug concentration in the release medium. The attached 
dip probes along with the mirror and optical path slit are immersed into the release me-
dium in the temperature and stirring controlled glass vials. The light beam is directed to 
the liquid through the optical path slit and then gets reflected by the mirror. Thus, the 
absorption spectra of the solute are collected in real time (84,87). 
 
Fig. 3.4: Schematic view of a µDiss vial with the sample and an immersed measuring 
probe (Adapted from (88)) 
3.5    Surface Profiling using Stylus Profiler 
The stylus profiler is a high-sensitive surface analyzer that is used to measure thickness 
and roughness of a surface. An overview of a Tecnor Alpha-step IQ stylus profiler 
hardware and its software (Alpha-step IQ) is shown in Fig. 3.5. The upper part of the 
software window consists of different scanning parameters that can be set for control-
ling the stage and stylus movement as well as data analysis.   
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Fig.  3.5: Tencor Alpha Step Stylus Profiler, sample loading and scanning of sample 
surface for thickness measurement 
This instrument is equipped with a video camera that shows the surface of the substrate 
and the red crosshair stylus apex as it keeps moving along the measuring surface. The 
stylus’ apex or curvature has a radius of 5 µm only. On the other hand, lower part of the 
window is for measurement display as the scan is performed. For loading the sample, 
the stage is put down as shown in Fig. 3.5 where the parameters used during the thick-
ness measurement are also displayed. If the sample seems to be too light and small, it is 
better to attach the sample to the loading stage, using lightly sticky double sided tape in 
order to avoid movement of the sample itself while the stylus is passing across it (Fig. 
3.5). The movement of loading stage in x, y directions is controlled by the knobs locat-
ed on the left side of the equipment. The equipment can measure samples with 150 mm 
diameter max and up to 15 mm of thickness. It can scan up to 10 mm horizontal and 2 
mm vertical surface. (Tencor Alpha Step).  
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3.6    Scanning Electron Microscopy  
The scanning electron microscope (SEM) produces images by generating a variety of 
signals at the solid specimens’ surface utilizing focused beam of high energy electrons. 
These electron-sample interactions driven signals provide information regarding the 
surface morphology, chemical composition, structure and orientation of materials of the 
scanned sample (89). Compared to other conventional optical microscope, SEM has 
higher magnification with exceptionally good resolution. It also offers larger depth of 
field and requires minimal specimen preparation (90). 
 
Fig. 3.6: Schematic overview of a scanning electron microscope  
(Adapted from (91)) 
The fundamental principle of SEM lies in accelerated electrons that carry significant 
kinetic energy which is subsequently dissipated as variety of signals by electron-sample 
interactions. Signal specific detectors then detect the scattered electrons and amplify 
them to be projected in the display. Essential components of SEM include electron gun 
or source, electron lenses, sample stage, detectors of signals, display or data output de-
vice and other infrastructure requirements such as vacuum system, pump and power 
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supply (Fig. 3.6). Most SEM has more than one detector for capturing signals (89). Fur-
ther details regarding the SEM used in this study are provided later.  
3.7    X-ray Photoelectron Spectroscopy  
The x-ray photoelectron spectroscopy (XPS), also known as electron spectroscopy for 
chemical analysis (ESCA), is a surface-sensitive, quantitative, non-destructive tech-
nique that can measure the elemental compositions including empirical formula, elec-
tronic state, and chemical state in a compound. This instrument requires high vacuum or 
ultra-high vacuum conditions and it can detect all atomic elements except hydrogen and 
helium. The average depth analysis of XPS is about 5 nm (92,93).   
 
Fig. 3.7: Emission of photoelectron by x-ray beams (Adapted from (92)) 
The fundamental principle of XPS is to excite sample surface with mono-energetic Al 
kα x-rays, while simultaneously measuring the emitted electrons and kinetic energy 
(Fig. 3.7). Thus, by counting the emitted electrons over a range of kinetic energy, a pho-
toelectron spectrum is obtained.  Analyzing the binding energy and the intensity of a 
photoelectron peak, the identity of the particular component, its chemical state and the 
quantity of the detected element can be determined.  Fig. 3.8 presents a diagram of the 
essential components of a XPS which includes x-ray source, detector, camera, ion gun, 
flood gun, lamp, sample holder, and analyzer. (93).  
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Fig. 3.8: Schematic view of XPS equipment showing the location of the major compo-
nents (Adapted from DTU Danchip Manual for XPS-ThermoScientific 2015) 
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4. MATERIALS AND METHODS 
This chapter mentions the materials and explains the stepwise methodology of develop-
ing polymeric lids of microcontainers leading to targeted drug delivery. In addition, this 
section illustrates the lid stability tests and validation experiments. The study was divid-
ed into six major parts. The parts are shown in Chart 4.1 below: 
 
Chart 4.1: Major experimental steps of the study 
4.1 Preparation of Amorphous Sodium Salt of Furosemide  
Amorphous sodium salt of furosemide (ASSF) was prepared using a Mini Spray Dryer 
(B-290 No. 1, Büchi, Germany). For the ASSF preparation, 4.0 g of furosemide (Sigma 
Aldrich) was mixed with 100 ml of 96% Ethanol and 2.5 ml of 5M NaOH. Finally, 
897.5 ml of miliQ water was added to the solution to obtain 4 g/L (12.085 mM) of final 
drug concentration. The solution was protected from light and was stirred on a magnetic 
stirrer at a temperature of 55o C for about 45 minutes followed by spray drying the solu-
Step 1
• ASSF (drug) Preparation
Step 2
• Loading of Microcontainers
Step 3
• Polymer Solutions Preparation
Step 4
• Adjuvant-Based Polymer Lid Formation
Step 5
• pH-Sensitive Polymer Lid Formation 
Step 6
• Drug Release Test 
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tion using spray dryer.  The parameters of the spray dryer settings were identical to 
studies published in literature (39,41) are given below in Table 4.1. 
Table 4.1: Parameter settings of the spray dryer for preparation of ASSF  
Parameters Values 
Inlet temperature (o C) 200 
Aspirator (%) 80 
Pump (%) 10 
Atomizer (mm) 40 
A de-humidifier (Buchi B-290) was used with the spray dryer equipment for drying the 
drug solution during the process. Fig. 4.1 shows the setup of spray dryer, parameter set-
tings and the preparation of ASSF drug.  
 
Fig. 4.1: Spray dryer setup and preparation of Amorphous Sodium Salt of Furosemide 
(ASSF) 
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After the spray drying, the ASSF drug was extracted from the collection chamber and 
transferred to another vial. The ASSF vial was then wrapped with aluminum foil and 
placed inside a desiccator to avoid contact with outside air.  
In order to calculate the yield, the empty collection chamber was weighted prior to us-
ing the spray dryer. After the spray drying process, the spray dried ASSF and the collec-
tion chamber were weighted. Thus, the yield calculation was done using the following 
formula.  
Yield = 
𝐴𝑐𝑡𝑢𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑃𝑟𝑜𝑑𝑢𝑐𝑒𝑑 𝐴𝑆𝑆𝐹
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝐹𝑢𝑟𝑜𝑠𝑒𝑚𝑖𝑑𝑒 𝑝𝑜𝑤𝑑𝑒𝑟
∗ 100 
4.2    Loading of Microcontainers (MCs) with ASSF 
 ASSF was loaded into the microcontainers by the powder embossing method. Fig. 4.2 
below shows SU-8 microcontainers on silicon chips which were fabricated in the clean-
room (DTU Danchip, Denmark).  
 
Fig.  4.2: SU-8 microcontainers on silicon chips  
In the beginning of loading, the desired amount of ASSF was taken onto the shadow 
mask drug holder (Fig. 4.3). Next, the shadow mask was placed on top of the sample 
chip followed by placing both into the shadow mask frame.  
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Fig. 4.3: The various parts of shadow mask for loading the MCs using an embossing 
method 
Finally, the shadow mask-fitted sample chip is placed on top of the drug at the drug 
holder. After proper placement, 2kN of pressure is applied at room temperature and thus 
the drug gets loaded inside the MCs of the silicon chip. Fig. 4.4 below shows the 
placement of the silicon chip containing MCs and the orientation of the shadow mask 
on top of the bonding press metal plate for loading.  
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Fig.  4.4: Loading of ASSF drug using a shadow mask in bonding press 
Each chip was assigned a number and the weights of the chips had been recorded using 
a microbalance before and after loading in order to calculate the amount of drug loaded 
into each specific chip. It is important to know the weight of loaded drug into each chip, 
so that during the release test in micro dissolution apparatus, the concentration and dis-
solution percentage of the drug from each chip can be calculated.  
Amount of loaded drug = (Weight of chip after loading – Weight of chip before loading) 
Drug concentration = 
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑙𝑜𝑎𝑑𝑒𝑑 𝑑𝑟𝑢𝑔 (𝑚𝑔) 
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑚𝑒𝑑𝑖𝑢𝑚 (𝑚𝐿)
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4.3    SEM Imaging of  Loaded Microcontainers 
After sample loading, the quality of loading was analyzed using SEM imaging. Here, 
the loading quality refers to the number of MCs loaded with drug, quantity of loaded 
drug in the MCs, number of MCs broken or fallen off during the powder embossing 
process using the bonding press.  
Fig. 4.5 shows the drug loading analysis under a tabletop SEM (Phenom Pro), whereas 
the Fig. 4.6 presents an overview of a supra SEM (Zeiss). 
 
  
Fig.  4.5: Sample analysis under a Tabletop SEM  
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Fig.  4.6: Overview of a Supra SEM and sample analysis  
Since most of the (almost 98% of the) sample analysis was performed using supra SEM, 
therefore, this section describes the methodology of supra SEM imaging. The analysis 
began with sample mounting on the SEM sample holder. After mounting the samples, 
the instrument was vent and pumped down. Then the sample holder with the samples on 
top of it was mounted inside the SEM. In case of blank sample (e.g. empty SU8 micro-
containers on silicon wafer), the sample was coated with thin gold layer using Sputter 
Coater 03 (Cressington 208HR) in order to reduce problems with charging on sample 
during SEM analysis. After the samples were inside the SEM, the stage was pumped 
down and the high voltage extra high tension (EHT) was turned on. Depending on the 
sample type and the analysis, different parameters such as working distance (WD), aper-
ture alignment, stigmation, EHT and type of detection lens were optimized. Table 4.2 
below shows some of the important parametric values that were used for analyzing the 
MCs in the supra SEM.  
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Table 4.2: Some important parameters of SEM imaging 
Parameters Values 
Vacuum mode Both HP & VP 
Detectors Both SE2 & VPSE 
Tilt 30° 
EHT 8-18 kV 
WD 8-12 mm 
Once the image was optimized enough to be captured, it was saved for further analysis. 
The same procedure was followed for lid morphology investigation throughout this 
study.  
4.4    Preparation of Polymer Solutions 
In this section, the preparation of different polymer solutions for developing different 
lids on the drug-loaded MCs is presented. During this study, three types of Eudragit 
solutions and two types of chitosan solutions were prepared for different lids formation. 
4.4.1   Eudragit Solution with TEC  
This Eudragit solution contained 1% (w/v) Eudragit L100-55 (Evonic, Essen, Germany) 
with 15% TEC (Sigma Aldrich) and 6% mol of NaOH pellets in isopropanol (IPA). To 
prepare the solution, 2.0 g of Eudragit was first mixed with 150 ml IPA and 264 µl TEC 
and the mixture was stirred overnight at 700 rpm and at 45-50°C. After the solution 
turned transparent, 24 mg of NaOH was added to the solution and was let to solubilize 
for another day. The final volume of the solution was adjusted at 200 ml using addition-
al IPA to obtain a Eudragit solution with a concentration of 1%.  
4.4.2   Eudragit Solutions with DBS 
Two different Eudragit solutions were prepared using a plasticizer called DBS (Sigma 
Aldrich). The first type of Eudragit solution contained 1% (w/v) EL100-55, 6% mol of 
aqueous NaOH and 5% DBS. The process of preparing this solution was the same as 
that of the previous of EL solution which took about two days for the solution prepara-
tion.  
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The second type of Eudragit solution contained 1% EL100-55 with 5% DBS, without 
any NaOH. It took only about 6 hours of magnetic stirring to have a homogenous trans-
parent solution with a final concentration of 1% Eudragit. 
4.4.3   Chitosan Solution  
0.5% (w/v) chitosan solution was prepared in 0.1M acetic acid (AA). To prepare this 
solution, 0.5 g of low molecular weight (LMW) chitosan (Sigma Aldrich) was added to 
0.6 ml of pure AA. Finally, total volume of the solution was adjusted to 100 ml to ob-
tain a chitosan solution of 0.5% concentration.  The solution was stirred at 350 rpm 
using 50-55°C overnight. After a homogeneous solution was obtained, the solution was 
filtered at least 5 times using syringe filters with different pore sizes of 0.80, 0.45 and 
0.20 µm (Advantec) due to high impurity (about 18-20%), and it was then preserved in 
a glass bottle sealed with parafilm. 
4.4.4   Chitosan Solution with MPLA 
Unlike the previous chitosan solution, this solution contains an adjuvant, called MPLA 
(Avanti, 699800P). This solution contained 0.5% (w/v) of LMW chitosan with 3% 
(w/w) MPLA in 0.1M AA. To prepare this solution, 1.8 mg of MPLA was dissolved in 
180 µl of 1:4 methanol:chloroform solution. It took approximately 3 hours to complete-
ly dissolve the MPLA in the methanol-chloroform solution. Next, the MPLA solution 
was added to 12 ml of the 0.5% (w/v) chitosan dissolved in 0.1M AA. It took approxi-
mately 3 days to obtain a homogenous solution of MPLA and chitosan. The solution, 
however, contained negligible amount of impurities and therefore, was filtered twice 
using 0.80 and 0.45 µm pore sized syringe filters. Fig. 4.7 shows the chitosan-MPLA 
solution below.   
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4.5    Adjuvant-Based Polymer Lid Formation 
The purpose of developing chitosan lid was to incorporate an adjuvant (e.g. MPLA) into 
it. Since MPLA is an expensive adjuvant, in the beginning of the study, only chitosan 
lid was spray coated in order to test its stability and ability to permeate drug at targeted 
pH medium.  
A spray coater (Exactacoat, Sono-Tek Corporation, NY, USA) equipped with a Ac-
cuMist™ ultrasonic mini-spray atomizing nozzle (94) was used to spray the prepared 
chitosan solution on top of ASSF loaded SU-8 microcontainers fabricated on silicon 
chips (section 4.2). The spray coater has three main parts (Fig. 4.8)- i) Syringe Pump, ii) 
Spray Chamber, iii) Spray coater connecting computer, which has three particular soft-
wares (i.e. Generator control; Syringe pump; and Exactacoat portal version 1.0.3, build 
10/2009). The necessary parameters for spray coating are set by using these softwares 
(Table 4.3).  
Fig. 4.7: Chitosan-MPLA with impurities (left); Chitosan-MPLA after vortexing and fur-
ther stirring (middle); Chitosan-MPLA after twice filtration (right) 
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Fig.  4.8: Spray Coater for formation of the polymeric lids  
In this polymeric lid formation process, following the cleaning and optimization steps, a 
20mL luer lock syringe (Braun) was filled with chitosan solution and clamped at the 
syringe pump which has a connected motor to pump the solution from the syringe into 
the spraying tube inside the spray chamber. The ASSF loaded samples were placed in-
side the spray chamber on its hot plate. The spray chamber’s temperature, air shaping 
pressure and position of the spraying nozzle were adjusted prior to spraying the polymer 
solution. Table 4.3 represents the spray coating parameters used for chitosan lid for-
mation.  
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Table 4.3: Parameters for spray coating 0.5% w/v Chitosan solution in 0.1M Acetic 
Acid  
Spray Coater Manual Controllers 
Temperature   40 °C  Air Shaping Pressure   0.01 kPa  
Exactacoat Portal  
Wait Time 0.04 sec  Area  X2  
 Stall Point   0.5   CNTR   60 (x2) 
 Z   25   Path Speed   25 mm/sec  
Generator 
 Run Power   1.5 watts  Idle Power   0 watts 
Syringe Pump 
 Infuse Rate   0.100 ml/min   Syringe Diameter   20 mm  
In this study, 4 silicon chips containing MCs and 2 control chips without MCs were 
spray coated simultaneously and about 7 ml of chitosan solution was used for the given 
parameters and the coating area.  
The total spray duration for the chitosan coating completion was 1 hour and 15 minutes. 
The same protocol and parameters were used to spray coat both chitosan solutions, with 
and without the adjuvant MPLA. SEM images were taken to analyze the lid morpholo-
gy following the lid formation.  
4.6    pH-Sensitive Polymer Lid Formation 
A pH-sensitive polymer solution, EL100-55 was spray coated on top of the above-
mentioned chitosan lid, so that the chitosan lid can be protected in gastric medium but 
be exposed at the small intestine medium in order to ensure targeted drug delivery. As 
described in the polymer solution preparation Subsection 4.4.1-4.4.2, three types of 
EL100-55 solutions were prepared to form pH-sensitive lid. Despite the differences in 
the chemical types and amounts and process of solution preparations, the spray coating 
parameters and method were the same for all the EL100-55 solutions. However, differ-
ent counter numbers of passes (CNTR) of the nozzle of the spray coater were tested to 
determine an effective thickness of the spray coated EL lids. It is worth-mentioning that 
1 CNTR refers to1 full coverage of the nozzle movement from one end of the spray 
coating area (or sample area) to the other end. The parameters used in this process are 
presented in Table 4.4.  
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Table 4.4: Parameters for spray coating 1% w/v Eudragit L100-55 solution and Iso-
propanol solvent 
Spray Coater Manual Controllers 
Temperature   40 °C  Air Shaping Pressure   0.02 kPa  
Exactacoat Portal 
Wait Time 0.04 sec  Area  X2  
 Stall Point   0.5   CNTR *  60 (x2) 
 Z   35   Path Speed   5 mm/sec  
Generator 
 Run Power   2.2 watts  Idle Power   0 watts 
Syringe Pump 
 Infuse Rate   0.100 ml/min   Syringe Diameter   20 mm  
*CNTR 60 and 20 were used during the EL100-55 which gave different thicknesses in 
the lids 
Likewise the chitosan lid formation, 4 silicon chips containing MCs and 2 control chips 
without MCs were spray coated simultaneously with EL solution. For the given parame-
ters and the coating area, 11 ml of EL solution was needed during the 2 hours of spray-
ing. Fig. 4.9 presents the optical microscopic view of the samples before and after spray 
coating with EL100-55.   
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Fig.  4.9: Optical microscopic view of MCs after loaded with ASSF and then, again 
after spray coated with 1% Eudragit L100-55 solution 
Following the lid formation, the lid morphology analysis was performed in supra SEM 
(Zeiss). The drug-loaded samples with polymeric lids were then carefully preserved in a 
sample holder box, kept inside a desiccator away from light for the release study in 
µDiss profiler, as the next step. On the other hand, the spray-coated plane silicon wafers 
without MCs were utilized for thickness measurement.   
4.7    Lid Thickness Measurement in Stylus Profiler 
A stylus profiler (Tecnor, Alpha-step IQ surface profiler) was used to measure the 
thickness of the lid for all the samples throughout this study. The sample or the polymer 
lid was spray coated in the middle part of a plane silicon wafer (Fig. 4.10 A) so that the 
stylus runs from one side of the silicon wedge to the other wedge where plane silicon 
would be present (Fig. 4.10 B and C). Thus considering both wedges of the plane sili-
con wafer as zero height level or ground, the measurement profile would calculate the 
ASSF drug 
EL polymer coating 
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height or the thickness of the lid spray coated in the middle part of the wafer. Therefore, 
a center bias adjustment was chosen in the parameter settings, as presented in Table 4.5.  
 
Fig.  4.10: A. Sample (polymer lid) for thickness measurement has been prepared using 
spray coater; B. Sample for thickness measurement is ready to go into the stylus profil-
er; C. Video camera showing the movement of the stylus on the polymeric lid surface as 
indicated by a red crosshair; D. Thickness profile in the measurement window 
Table 4.5: Parameter settings for thickness measurement of polymeric lids 
Parameters Values 
Scan length 5000-7000 µm  
Scan speed 100 µm/s 
Sampling rate 50 Hz 
Resolution 2 µm 
Sensor range 550 µm / 32.8 pm 
Contact speed 3 
Adjustment Central bias 
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4.8    Lid Stability Test 
Prior to performing the actual release study, the lid stability tests were done three times 
using glass slides, plane silicon chip with no MC and lastly, silicon chips containing 
SU-8 MCs with and without drug, in two separate pilot studies.  
In the 1st pilot study, the lid stability tests were performed with glass slides in standing 
buffer solutions. When the results turned out positive, then in the 2nd pilot study, the lid 
stability was tested on magnetic stirring plate mimicking the actual release test parame-
ters, such as rotation, temperature and volume of the release medium, in order to deter-
mine whether the polymeric lids of the ASSF-loaded MCs are stable and thus ready to 
go through the actual release test in a µDiss profiler.   
4.8.1 Lid Stability Test in Standing Buffer Solutions 
In the 1st pilot study, glass slides were spray coated with EL100-55 solution. In this test, 
firstly100 mM of phosphate buffer was prepared with pH 3.5 and pH 5.0, separately. 
The glass slide spray-coated with polymer lid was dipped into the phosphate buffer of 
pH 3.5 (pH of mice stomach (95)) for 2 hours and then the lid was analysed under an 
optical microscope (Zeiss). Next, the same sample was dipped into another phosphate 
buffer of pH 5.0 (pH of mice small intestine (95)) for 4-5 hours and was analysed again 
under the same microscope as shown in Fig. 4.11. Unlike the 2nd pilot study, the thick-
ness measurement under the stylus profiler was not done during the 1st pilot study.  
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Fig.  4.11: Lid stability test using glass slide in standing buffer solutions and then, the 
lid morphology analysis under an optical microscope 
In another stability test in standing buffer solutions, plane silicon wafer was used in-
stead of glass slides. Also, double lids – both EL and chitosan polymers, were spray 
coated during this experiment as shown in Fig. 4.12. First of all, a part of the silicon 
wafer was covered with aluminum foil and then the wafer was spray-coated with chi-
tosan solution. Then the aluminum foil cover was extended further to cover up half of 
the spray-coated chitosan lid. Once the half of the chitosan lid and the plane silicon 
wedge were secured, then the EL100-55 was spray coated. At the end of double spray 
coating, thus there were three different sections or surfaces on a single silicon wafer- 1. 
plane silicon surface; 2. chitosan lid surface; and 3. EL100-55 lid surface (Fig. 4.12). 
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Fig.  4.12: Spray coated double lids (EL and Chi polymers) on silicon wafer for lid sta-
bility analysis 
 
Fig.  4.13: A. Eudragit L100-55 lid; B. Chitosan lid; C. A mixture of both EL and Chi-
tosan lids on silicon wafer under a table top SEM view 
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The lids were analyzed under table top SEM for morphology study. The SEM images 
presented in Fig. 4.13 show that the EL100-55 lid has many porous structures or shapes; 
whereas the chitosan lid looks very smooth and plain. The differences between these 
lids are more obvious and comparable in Fig. 4.13 C where both polymers mixed to-
gether during spray coating. The lid stability tests were run in both pH 3.5 and pH 5.0 
similar to the samples on glass slides.  
4.8.2 Lid Stability Test on Magnetic Stirrer 
The 2nd pilot study of the lid stability test was quite similar to the Section 4.8.1. Howev-
er, the difference with the previous pilot study was that instead of standing buffer solu-
tions, magnetic stirrer was used mimicking some of the parameters of the real release 
study. In addition, the thickness of the stable EL lid and Chi lid were measured in a sty-
lus profiler and their surface texture and smoothness were noted.  
Following the lid formation and thickness measurements, the samples were exposed to 
100 mM phosphate buffer at pH 3.5 for 2 hours and then at pH 5.0 for 5-7 hours. Simi-
lar to the actual release test in µDiss Profiler (Section 4.9), 37°C temperature, 100 rpm 
stirring speed and round µDiss stirring magnets were used during this study (Fig. 4.14).  
 
Fig.  4.14: Lid stability test on magnetic stirrer with a rotation of 100 rpm and at 37 °C 
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After the lid stability experiment, the samples were analyzed under an optical micro-
scope (Zeiss) (Fig. 4.15).  This experiment was repeated three times in order to confirm 
the stability of both the EL polymer lid and the chitosan lid.   
 
Fig.  4.15: Sample analysis for lid stability test under optical microscope  
4.9    Drug Release in a µDiss Profiler 
Following the lid formation and the successful lid stability pilot studies, the ASSF-
loaded samples with polymeric lids were ready for the drug release test in a micro disso-
lution apparatus.  The instrument consisted of a µDiss Profiler (Pion Inc), a UV spec-
trophotometer (Rainbow Dynamic Monitor System) and a mini batch (Struers KEBO 
Lab Julabo). The temperature of mini batch should be adjusted according to the re-
quirement of the experiment and for this study, it was set as 37 °C. Fig. 4.16 shows the 
µDiss Profiler apparatus used during the entire study. 
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Fig.  4.16: Micro Dissolution profiler and its parts for drug release test 
Cross magnets were used during making standard curves and round magnets were used 
in release test percentage dissolution curves. However, 1 mm mirrors were used for all 
of the release tests during both standard and dissolution curves.  
Chemicals needed for the release test were Furosemide (Fagron), Potassium Phosphate 
Monobasic or KH2PO4 (Sigma), PBS tablet (Sigma-Aldrich), 5M NaOH, 1M HCL and 
MiliQ water. The methods for preparing the buffer and standard solutions are described 
below.  
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4.9.1 Preparation of Phosphate Buffers 
2.72 g of KH2PO4 was used in miliQ water to prepare 200 ml of 100 mM phosphate 
buffers (Fig. 4.17). The appropriate pH value was adjusted by using either 1M HCL for 
or 5M NaOH.   
 
Fig.  4.17: Preparation of phosphate buffer and pH adjustment 
4.9.2 Preparation of Furosemide Standard Solution 
250 mg of furosemide was weighed using a micro-balance and then a glass volumetric 
flask of 25 ml was used to dissolve the furosemide in miliQ water with a final volume 
of 25 ml. In this procedure, few drops of 5M NaOH were added to the solution to dis-
solve the furosemide prior to volume adjustment. Thus, 30.2 mM final concentration of 
the furosemide standard solution with a pH of approximately 10 was achieved.  
4.9.3 Preparation of Standard Curves 
Before the drug release experiment, standard curves were prepared in order to construct 
reference data points for UV absorbance spectra of the actual drug release. In this pro-
cess, 10 ml of buffer solution (either pH 3.5, or 5, or 6.0) was added into each µDiss 
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vial with star magnet, followed by placing them into the µDiss profiler. After the probes 
were connected and placed in the buffer medium, the instrumental software (Au PRO 
5.1) was run for setting the necessary parameters as presented below in Table 4.6.   
Table 4.6: Parameter settings for µDiss profiler 
Parameters Values 
Volume in Vials  10 ml 
Temperature 37 °C 
Detection Range 310-350 nm 
Baseline  710 nm 
Mirror or Path Length 1 mm 
Stirring Speed 100 rpm  
Molecular weight 331.0 g/mol  
Units of spectra mg/ml 
Next, a blank data point and then the standard data points were collected by adding fu-
rosemide standard solution into the buffer medium stepwise to collect spectrum for var-
ying concentration and volume. For the standard curve in pH3.5, a range of concentra-
tion from 0.01 mg/ml to 0.2 mg/ml was chosen; whereas it was 0.04975 mg/ml to 
1.6667 mg/ml for pH 5, or pH 6 (APPENDIX A). 
4.9.4 Release of ASSF from MCs and Preparation of Dissolution Curves 
For the drug release experiments, similar setup as described in (39, 41) were used. Five 
different protocols (Table 4.7) were used in order to test the efficacy of different lids. 
For the different protocols the required pH specific standard curve was used for prepar-
ing the dissolution curves.    
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Table 4.7: List of six different protocols for drug release test used multiple times to test 
both the stability of the polymer lids and the release of drug at targeted pH 
Protocol Purpose Polymer 
Lid 
Duration pH Buffer 
1 ASSF drug re-
lease from SU8 
MCs 
No Lid  21 hours 6.5 (e.g 
human 
small in-
testine) 
Phosphate 
buffer 
2 pH sensitivity of 
EL lid in mice 
stomach 
Eudragit 
L100-55 
(plasticizer: 
TEC) 
2 hours  
 
3.5 (e.g 
mice 
stomach) 
PBS 
5 hours 5.0 (e.g 
mice 
small in-
testine) 
3 pH sensitivity of 
EL lid in wild 
mice intestine 
Eudragit 
L100-55 
(plasticizer: 
DBS) 
2 hours  
 
3.5 (e.g 
rat stom-
ach) 
Phosphate 
buffer 
5 hours 6.0 (e.g 
rat small 
intestine) 
4 Capability of 
chitosan lid to 
disperse drug in 
mice intestine 
Chitosan  5-10 hours 5.0 (e.g 
mice 
small in-
testine) 
Phosphate 
buffer 
5 pH sensitivity 
and lid stability 
test of EL-
Chitosan double 
layer lids 
Eudragit 
L100-55 
(plasticizer: 
DBS) and 
Chitosan 
2 hours 3.5 (e.g 
rat stom-
ach) 
Phosphate 
buffer 
13 hours 6.0 (e.g 
rat small 
intestine) 
6 Development of 
pH sensitive (EL 
lid) adjuvant 
based polymer lid 
(Chitosan-
MPLA) 
Eudragit 
L100-55 
(plasticizer: 
DBS) and 
Chitosan-
MPLA  
2 hours 3.5 (e.g 
rat stom-
ach) 
Phosphate 
buffer 
19 hours 6.0 (e.g 
rat small 
intestine) 
Following the parameter settings, the samples were loaded into the µDiss profiler. As 
shown in Fig. 4.18, the drug-samples with polymeric lids were attached to the µDiss 
round magnets with the help of carbon pad and then were put in each vial and the vials 
were placed inside the µDiss profiler. 10 ml of 100 mM phosphate buffer were poured 
into each vial and then were airtight with parafilm and wrapped with aluminum foil in 
order to avoid light exposure during the release test. After the data point collection of 
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the drug release concentration was done, the drug dissolution % or percentage release 
was calculated in excel using the formula below.  
Drug Dissolution % = 
𝐷𝑟𝑢𝑔 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 𝑚𝑒𝑑𝑖𝑢𝑚 𝑜𝑣𝑒𝑟 𝑡𝑖𝑚𝑒 (𝑚𝑔/𝑚𝐿) 
𝐷𝑟𝑢𝑔 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑚𝑔/𝑚𝐿)
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Fig.  4.18: µDiss experimental setup for sample placement 
After each release test, the lid morphology and stability of the samples were analysed in 
SEM (Supra 40VP Gimini). In cases of those experiments involved in more than one pH 
medium as indicated in Table 4.7, after each release test it was highly important to per-
form the lid morphology study in order to determine if the experiment should further 
proceed for another pH medium. For example, if the lid was dissolved in gastric pH of 
3.5, then it would be pointless to run the release test further in the small intestine pH 
medium (pH 6.0).    
4.10    MPLA Detection in XPS  
For detecting the presence of adjuvant MPLA incorporated into the chitosan polymer 
lid, x-ray photoelectron spectroscopy (XPS, K-Alpha, Thermoscientific) was used. 
Three types of samples were prepared for the XPS detection. i. Piece of plain silicon 
wafer as a blank sample; ii. Silicon wafer spray coated with chitosan solution (Subsec-
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tion 4.4.3) as a control; and iii. Silicon wafer spray coated with chitosan-MPLA adju-
vant solution (Subsection 4.4.4).  
XPS samples have to be completely dry and stick to the sample holder tightly using 
small clips as shown in Fig. 4.19. Likewise SEM, the analysis chamber was vent prior 
to sample loading in the load-lock and the stage was pumped down after the loading 
using the instrumental software (Avantage; version 5.948). After the stage is pumped 
down to base pressure, the position is called the parking position. Next, the sample 
holder gets transferred to the stage inside the analysis chamber. The software window 
shows a platter view of the sample holder displaying the attached samples on it, and 
below that, a magnified live view of the analysis points. Once the experiment was run, 
the “Current Data View” showed the spectrum that was being recorded.  
 
Fig.  4.19: Samples loading and viewing in XPS equipment 
After the analysis, the samples were transferred back to the load-lock and the equipment 
was vent. After taking the samples out of the holder, the empty sample holder was put 
back into the load lock in order to minimize degassing from the sample holder followed 
by pumping down the stage.  
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5.    RESULTS AND DISCUSSIONS 
5.1    ASSF Drug Production Yield 
ASSF was produced by spray drying using two different protocols where the optimized 
protocol contained 25% larger amount of each chemical. Table 5.1 below presents the 
percentage yield of ASSF using the two protocols for a total of 4 batches of production. 
The yield from the various batches of ASSF was approximately between 62% and 74 %.  
Table 5.1: %Yield of ASSF during different experiments 
Protocol# Experiment# 
 
Date of 
Production 
Yield  
% 
Average 
% yield 
Standard  
Deviation 
1 
1-a 05-10-2016    61.5 
63.75 3.18 
1-b 26-10-2016    66 
2 
2-a 10-11-2016    73 
73.4 0.56 
            2-b    06-12-2016 73.8 
The results in Table 5.1 show that the new optimized protocol is more efficient since it 
has 73.4 +/- 0.56 % yield on average which is much higher in compared to the previous 
protocol. 
5.2    Loading of Microcontainers 
Loading of microcontainers with the embossing method was successful and the loading 
resulted in a load of about 4.2 µg of ASSF per MC on average. Using shadow mask for 
loading MCs, prevented deposition of drug in the empty space between MCs and thus, 
ensured precise loading. As shown in Fig. 5.1, SEM images were taken after the loading 
to ensure proper loading and notes were made regarding the loading quality. 
 
52 
 
 
Fig.  5.1: A. SEM images of empty MC; B. MCs loaded with ASSF using shadow mask 
Nevertheless, the loading was variable, due to several factors. For example, if the shad-
ow mask is not properly clipped on the sample, then the loading would not be precise 
and there would be drug deposition in between MCs and some MCs would be partially 
loaded, or completely unloaded. Also, some MCs might fall off, or even the silicon chip 
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might get broken due to misalignment of the shadow mask and the MCs.  As a result, it 
would give a wrong estimation of amount of drug loaded into each MC, as well as a 
biased drug release curve in the µDiss experiment.  
 
Fig. 5.2: SEM images showing improper sample loading (red) and properly loaded 
sample (yellow) 
Another factor was the surface condition of the shadow mask. Sometimes, due to using 
the same shadow mask for a long time, the shadow mask surface becomes rugged which 
also results in the above unfavorable circumstances, and thus biased release test results.  
Fig. 5.2 presents the SEM images of both a properly loaded and a poorly loaded sam-
ples.  APPENDIX B contains more images of ASSF loading using powder embossing 
method and APPENDIX C presents different shadow masks.  
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Nonetheless, using shadow mask in powder embossing method has been proven effec-
tive in a recent literature (80), where other drugs such as cubosomes and PVP were 
loaded successfully for vaccine delivery.  
5.3    Drug Release  from MCs without Lid 
ASSF  release from MCs without lid was performed to investigate if the drug can be 
released from the SU-8 microcontainers into the medium of pH 6.5 for 21 hours. In this 
study, phosphate buffer of pH 6.5 was chosen as the release medium in order to mimic 
the drug release in human small intestine. Fig. 5.3 shows the drug release  over time  
from five different µDiss channels for five individal samples and the gray curve 
represents the average of these five release curves.  
 
Fig.  5.3: Release Test of ASSF drug from SU-8 MCs in 100mM phosphate buffer of 
pH6.5 medium 
Except channel 2 (green curve), the other channels show very good drug release in pH 
6.5 medium. The reason of this exception might be an improper loading of the sample 
which ends up with less loaded drug and thus less release (APPENDIX B). Since there 
is no lid used on top of the MCs, therefore immediate and very fast drug release was 
observed from the all the samples.  These results replicate the results of similar litera-
ture in (43).  
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Unlike this experiment, in the following release tests with lids, the amount/weight of 
loaded drug in each sample was recorded prior to spray coating, so that the percentage 
dissolution of drug release can be calculated after the release test.  
 5.4    pH-Sensitivity and Drug Release Test with Chitosan Lid   
After the chitosan lid formation on the ASSF-loaded MCs, SEM investigation was done 
to analyze and record the lid morphology. The SEM images in Fig. 5.4 show that the 
chitosan lid was very smooth and homogenously formed over the MCs.  
 
Fig.  5.4: Chitosan lid morphology analysis under SEM 
Following the morphology analysis, the lid thickness was measured using stylus profiler 
(Fig. 5.5). The average thickness of the chitosan lid was found 6.62 +/- 0.29 µm in this 
experiment which is reproducible.  This experiment was repeated three times with 5 
samples in each, and the average thickness of chitosan lid was recorded as 6.20 +/- 0.3 
µm.  
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Fig.  5.5: Thickness measurement of chitosan lid on average 
 
Fig.  5.6: Release of ASSF from MCs coated with chitosan lid in phosphate buffer 
pH5.0 for 10 hours. The data represents the mean of 5measuremets±SD.  
After the thickness measurement, the samples with chitosan lid were tested in the re-
lease medium of pH 5.0 for the drug release in a µDiss profiler over 10 hours. The aver-
age dissolution results are plotted in Fig. 5.6 which shows that the avg. % of drug re-
lease almost saturates after 2 hours, and then there is a negligible increase in the release 
trend between 7 and 10 hours. This experiment however had issues like APPENDIX D 
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(Fig. D: A), and therefore it showed a lower release % compared to the other chitosan 
lid experiments. Similar release test performed in pH 6.0 medium, demonstrated above 
85% of release over 7 hours (Section 5.8).   
Chitosan lid morphology was analyzed after 5 and 10 hours of drug release in phosphate 
buffer of pH 5.0 which are depicted in Fig. 5.7 below.  
  
 
Fig.  5.7: A. Morphology of Chitosan lid after 5 hours of release test in phosphate buff-
er of pH 5.0; B. Chitosan lid after 10 hours of release test in phosphate buffer of pH5.0. 
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In comparison to the chitosan lid in pH 5.0 after 5 hours in Fig. 5.7A, the lid morpholo-
gy in Fig. 5.7B after 10 hours of release seems to be more lifted off the samples and 
also there are more holes and scars in the chitosan lid. In addition, some crystalline fu-
rosemide can be seen through the holes of MCs after the 5 hours of release test, where-
as, after 10 hours, almost no furosemide was found. This phenomenon complies with 
the average % release curve in Fig. 5.6 showing slight increase in the drug release. 
However, since the release of the drug after 10 hours experiment is not significantly 
different from the drug release after 5 hours, therefore, it suggests that most drug was 
released into the medium by 5 hours. Therefore, for the next chitosan release test, 5-7 
hours of duration was chosen, instead of a 10 hours long experiment.  
5.5    pH-Sensitivity and Drug Release Test with Eudragit Lid  
This section is divided into three subsections, where in the 1st subsection, the major re-
sults of the two pilot studies from Section 4.8 conducted to determine lid stability are 
shared. In this subsection, the EL100-55 lid morphology analysis after and before pH-
sensitivity test on standing buffer media from the 1st pilot study is discussed. Here, the 
pH-sensitivity of the EL100-55 lid was determined based on its stability in gastric me-
dium (e.g. pH 3.5) and dissolution in small intestinal medium (e.g. pH 5.0 and pH 6.0).  
In addition, this subsection also presents the average thickness measurements of EL100-
55 lid from the 2nd pilot study of the lid stability test.   
In the 2nd subsection, the pH-sensitivity and the drug release capacity of EL100-55 lids 
with 15%TEC plasticizer are analyzed, where different CNTR of coating and thus dif-
ferent lid thicknesses are examined. On the other hand, the 3rd subsection of Section 5.5 
discusses the efficiency of the pH-sensitive EL100-55 lid with 5% DBS plasticizer in 
terms of its drug release capacity in pH 6.0 medium. 
Lastly, the Section 5.5 ends with a summarized comparison table of different EL100-55 
lids in terms of their plasticizer, thickness, stability in gastric medium and drug dissolu-
tion capacity in small intestinal medium.  
5.5.1   Analysis of EL Lid on Glass Slide and its pH-Sensitivity Test Re-
sults 
This section analyzes the results from the lid stability tests mentioned in Section 4.8.1, 
performed using glass slides on standing buffer media of pH 3.5 and pH 5.0, respective-
ly.  
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After spray coating the EL100-55 solution on glass slide, half of the slide was dipped 
into the 100mM phosphate buffer solution of pH 3.5 for 2 hours first and then it was 
analysed under the optical microscope (Zeiss) as shown below in Fig. 5.8. 
 
Fig.  5.8: The EL lid on glass slide exposed to phosphate buffer pH3.5 for 2 hours 
No significant difference was visible after the exposure of the EL lid to pH 3.5 medium 
which is the gastric pH of mice, and thus the finding meets the hypothesis that the EL 
lid remains stable in gastric medium.  
Then the same part of the glass slide was dipped into 100mM phosphate buffer of pH 
5.0 for 5 hours and the optical microscopic view of the lid morphology is presented in 
Fig. 5.9 below.  
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Fig.  5.9: The EL lid on glass slide, which was exposed to pH 3.5 for 2 hours earlier, is 
now exposed to phosphate buffer pH 5 for 5 hours 
Unlike Fig. 5.8, the optical microscopic view of the above lid in Fig. 5.9 shows big 
pores or porous structures on the EL lid. It indicates that the EL has started to decay and 
it is no longer as stable as before. However, the hypothesis was that the lid would com-
pletely be dissolved in pH 5.0 medium, the small intestinal pH of mice, and thus the 
encapsulated drug from microcontainers would be released in the small intestine.   
Nevertheless, as the lid is partially dissolved with many porous structures on it, the next 
trial experiments focused on the lid thickness as well as the spray coating CNTR or 
number of passes in order to develop a lid with convenient thickness which would prob-
ably meet the hypothesis. The Fig. 5.10 captures the event in a nutshell.  
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Fig.  5.10: Eudragit lid stability and pH sensitivity test on a glass slide in phosphate 
buffer solution of pH 3.5 and pH 5.0 
Similar to the 1st pilot study, the lid morphology analysis of the 2nd pilot study on 
ASSF-loaded and EL coated samples proves part of the hypothesis that the EL lid re-
mains intact in the gastric pH value. However, it does not dissolve in the small intestinal 
pH value and thus partially meets the hypothesis. The results are presented in Fig. 5.11 
below.  
 
Fig.  5.11: The stability and pH sensitivity test of ASSF-loaded MC coated with EL100-
55 lid on a magnetic stirrer in 100mM phosphate buffer solutions of pH 3.5 for 2 hours 
and of pH 5.0 for 5 hours, respectively 
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The thickness of this EL100-55 lid measured in stylus profiler was found 65.8 +/- 1.8 
µm on average of 10 measurements (Fig. 5.12).  
 
Fig. 5.12: Thickness measurements of EL100-55 lid using a stylus profiler 
In Fig. 5.12, the x-axis shows the scan leanth of stylus profiler and the y-axis is the 
height or thickness of the polymer lids. The scan area from 0-1400 µm indicates the 
area covered by Eudragit lid, whereas 8000-9000 µm is  the plane silicon surface.  
Following these pilot studies, EL100-55 lid was tested in vitro in µDiss profiler to 
investigate the drug dissolution from MCs coated with the EL lid in different pH media 
as described in the following subsections.   
5.5.2   Analysis of Eudragit L100-55 lid containing TEC Plasticizer 
1% w/v EL100-55 solution mixed with 15% w/w TEC was spray coated on top of the 
ASSF-loaded MCs to form the pH-sensitive EL lid. Fig. 5.13 shows the SEM investiga-
tion of the EL lid spray coated with a CNTR of 60.   
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Fig. 5.13: Lid morphology analysis of 1% EL100-55 lid with 15% TEC plasticizer 
(Spray CNTR=60) 
After the release test in pH 3.5 buffer medium for 2 hours, the SEM images revealed 
that the EL lid was completely intact which meets the first part of the hypothesis that 
the lid would survive in gastric pH of mice. Therefore, the next step was to let the lid to 
be exposed to small intestinal medium i.e. 100mM phosphate buffer medium of pH 5.0 
for 5 hours. After 5 hours exposure, the SEM images show some rifts and holes in the 
EL lid, but the lid was not completely dissolved (about 5%) and thus it did not meet the 
second part of the hypothesis.  
The thickness of the EL lid measured in a stylus profiler was 63.5 +/- 2.4 µm on an av-
erage of 9 measurements. It was anticipated that the thickness of the EL lid might be the 
reason of not dissolving the lid completely in pH 5.0. Therefore, the next study focused 
on the lid thickness using the same polymer solution, while only the CNTR of spray 
coating was decreased to 15, instead of 60 in order to form a much thinner lid. After 
spray coating the polymer with CNTR=15, the thickness measurement in stylus profiler 
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is shown in Fig. 5.14. The average thickness of the lid was 9.86 +/- 0.39 µm after 10 
measurements, which is more than 6 folds thinner than the previous EL lid.   
 
Fig. 5.14: Thickness measurement of EL100-55 lid (contains 15% TEC) after spray 
coating with CNTR = 15 
In addition, the surface roughness of the new lid was much higher than the previous EL 
lid as indicated by the surface noise of the stylus profiler. The SEM images prior to the 
release test also reveal that the lid morphology was very uneven and patchy with irregu-
lar ups and downs (Fig. 5.15). The reason might be a combination of both thinner lid 
and poor loading of samples.   
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Fig. 5.15: Lid Morphology of EL100-55 lid with 15% TEC after spray coating with 
CNTR = 15 
After the thickness measurement and the lid morphology analysis, the drug release test 
was performed in pH 3.5 release medium (Fig 5.16). 
 
 
Fig. 5.16: Release Curves of ASSF from SU-8 MCs coated with EL100-55 polymer 
(15%TEC) with 15 passages. The data presents mean of 4 measurements ± SD.  
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The drug release experiment was run for 2 hours but the release curves in four individu-
al samples (Fig. 5.16) show that the drug release was very fast which occurred between 
5-10 minutes and after 20 min of the release test, all the curves reach almost the satura-
tion level indicating the completion of the drug release. From these results, it is assumed 
that the thickness of the lid was too thin to survive for more than 15-20 min. These re-
sults are also supported by the SEM images in Fig. 5.17 where the trace of EL100-55 lid 
could barely be found after the release test in pH 3.5 buffer medium. Moreover, a lot of 
white crystalline furosemide is all over the samples outside the SU-8 MCs. This phe-
nomenon proves that the number of passages (CNTR) during spray coating should be 
increased in order to maintain an optimum thickness which can survive in pH3.5 (gas-
tric medium), but gets dissolved in pH5.0 or higher (small intestinal medium).  
 
Fig. 5.17: Morphology analysis of EL100-55 lid with 15% TEC (CNTR = 15) after the 
release test in pH 3.5 medium for 2 hours  
At this point, it was anticipated that along with the thickness issue (i.e. number of spray 
coating passes, or CNTR), the plasticizer might play an important role in EL lid stability 
as discussed in several literatures (61–65, 96). Therefore, the hydrophilic plasticizer 
TEC used in the preparation of EL solution was replaced by a hydrophobic plasticizer 
called DBS (di butyl sebacate). The differences between these two plasticizers in terms 
of their physio-chemical properties are discussed earlier in Subsection 2.8.3.  
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5.5.3   Analysis of Eudragit L100-55 lid containing DBS Plasticizer 
1% w/v EL100-55 solution mixed with 5% w/w DBS was spray coated on top of ASSF-
loaded MCs to form the Eudragit lid. The CNTR during spray coating was adjusted at 
20 in order to investigate if it can survive in pH 3.5 medium and gets dissolved in pH 
5.0 medium, supporting both parts of the hypothesis.  
 
Fig. 5.18: SEM images of samples spray-coated with 1% Eudragit polymer containing 
5% DBS (CNTR = 20) 
The lid morphology analysis following spray coating Eudragit solution with DBS plas-
ticizer looked robust from the SEM images depicted in Fig. 5.18. Compared to Fig. 5.15 
(CNTR=15), the lid in Fig. 5.18 (CNTR=20) looks much intact and properly covering 
the drug-loaded MCs.  
The average thickness of this EL lid measured using the stylus profiler (Fig. 5.19) was 
42.96 +/- 5.51 µm which is almost 4 times thicker than the previous EL-lid containing 
TEC. However, the standard deviation of this new lid seems much higher than before 
despite having less rough surface. The different location of the samples inside the spray 
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coater hot plate might be the reason of this phenomenon. For instance, if the silicon wa-
fer is placed very near to the spray coater fan, then due to air blow, the lid layer on the 
silicon wafer becomes thinner and the lid surface looks rougher, compared to the lid on 
the silicon wafer that is placed far away from the fan.  
 
Fig.  5.19: Thickness measurement and analysis of Eudragit-DBS lid in Stylus profiler 
These samples were then put into the release test using magnetic stirring following the 
method of the 2nd pilot study. After the release test in pH3.5 (100 mM phosphate buffer) 
for 2 hours on magnetic stirring at 37 ºC, the SEM images reveal that the Eudragit-DBS 
lid is completely intact (Fig. 5.20).  
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Fig. 5.20: SEM view of EL lid containing 5% DBS (CNTR=20) after being in buffer 
medium of pH3.5 for 2 hours on magnetic stirring 
After the lid morphology analysis, the samples were further put in the 100mM phos-
phate buffer of pH5.0 on magnetic stirring for 5 hours at 37 ºC. After the release test, 
the lid morphology was analysed using SEM again which shows that the lids were not 
completely dissolved (Fig. 5.21).  
 
Fig. 5.21: Morphology of EL lid containing 5% DBS (CNTR=20) after being in buffer 
solution of pH5.0 for 5 hours on magnetic stirring 
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In Fig. 5.21, only about 25% of the EL-DBS lid was dissolved. Likewise almost all the 
previous experiments with Eudragit lid performed in this study, the lid was meeting the 
first part of the hypothesis by being intact in pH 3.5 medium, however it was not align-
ing with the second part of the hypothesis which expects the lid to be completely dis-
solved in pH 5.0 medium. Therefore, it was decided to let the samples to be in the same 
pH 5.0 medium for another 5 hours and analyze the lid morphology after a total of 10 
hours exposure to the pH 5.0 medium. However, the SEM images of the EL lids even 
after 10 hours of exposure at pH 5 medium (Fig. 5.22) shows the similar result i.e. the 
lids are not completely dissolved. About 70% of the lid was still intact.  
 
Fig. 5.22:  Morphology of EL lid containing 5% DBS (CNTR=20) after being in buffer 
solution of pH5.0 for 10 hours on magnetic stirring 
After all these experiments with changes in the CNTR, plasticizers and duration of re-
lease test, it was not possible to get the Eudragit L100-55 lid to be dissolved in pH5.0 
medium. Hence, release medium of higher pH value was chosen for this part of the 
study. As rat has the intestinal pH value of 6.0 (95), therefore, the release experiments 
were performed in 100Mm phosphate buffer of pH 6.0 mimicking the small-intestinal 
medium of rat instead of domesticated mice.  
The next experiment was exactly the same as the previous one; except the pH value was 
6.0 instead of 5.0 in the second release test. The release test in pH 3.5 after 2 hours 
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showed in SEM analysis that the lid was completely intact as the previous experiments 
and thus meets the 1st part of the hypothesis. Next, the samples were put in the second 
release test where the release medium had pH 6.0. After running the release test for 7 
hours in µDiss profiler, the samples were analyzed using SEM (Fig. 5.23).  
 
Fig. 5.23:  SEM images of samples with Eudragit -DBS lid after its exposure to pH6.0 
medium for 7 hours in µDiss profiler 
The SEM images above show that the Eudragit lid was completely dissolved after being 
in 100mM phosphate buffer of pH6.0 for 7 hours, finally meeting the 2nd part of hy-
pothesis. 
The percentage dissolution curve of both the release tests at pH 3.5 and pH 6.0 are pre-
sented in Fig. 5.24 below.  
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Fig. 5.24: A. Average % Release of ASSF in buffer pH 3.5 for 2 hour; B. Average % 
ASSF dissolution during the release test for 7 hours in buffer of pH 6.0. The data repre-
sents an average of 4 measurements ± SD.  
The % release study shows how fast the drug started to get released into the medium 
from the SU-8 MCs which were sealed with EL lid as well as the nature or trend of the 
release.  
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After the release test, the percentage dissolution curve was calculated as shown in Fig. 
5.24 A. For the first 1 hour, the %dissolution was below 10% on average and then in the 
last hour, there was very slight increasing trend in the release curve showing up to 16-
17% of drug release as maximum.  The drug release results in pH 6.0 buffer medium 
presented in Fig 5.24 (B) shows that the trend of the average dissolution curve swiftly 
increases till 2.5 hours and reaches highest plateau of the drug release (i.e. 81%). After 
that, the average release curve reaches its stationary level which indicates that the Eu-
dragit lid was completely dissolved after 2.5 hours during the release test in pH 6.0 me-
dium.  
Comparing the average % release of ASSF in pH 3.5 and pH 6.0 for 2 hours and 7 
hours, respectively for the same samples (n=4) with the same EL lid (containing 5% 
DBS), it can be seen that the average % dissolution in pH 3.5 medium is very negligi-
ble, whereas it is above 80% in pH 6.0 medium.  It suggests that this Eudragit lid satis-
fies both parts of the hypothesis and its pH sensitivity is stable for the gastric environ-
ment as well as for small intestine of rat.  
Fig. 5.25 demonstrates comparison between morphology of EL lids (1% w/v EL with 
5% w/w DBS) spray coated using different CNTR number. In addition, a comparison 
table (Table 5.2) is provided below to summarize the differences between the different 
Eudragit L100-55 lids tested during this study.  
 
Fig. 5.25: Lid morphology analysis of EL lid with different spray coating CNTR 
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Table 5.2: Comparing differences in different EL lids in terms of their composition, 
thickness and pH sensitivity in gastric and intestinal media 
EL Lid com-
position 
Spray 
coating 
CNTR 
Avg. Thick-
ness (µm) 
Stability in pH 
3.5 medium 
after 2 hours 
Stability in pH 5.0 
medium           
after 5 hours 
Eudragit 
L100-55 with 
15% TEC 
60 63.50 +/- 2.40 
83.41 +/- 3.57* 
125.0 +/- 1.70* 
Very stable  Partially dissolved 
(about 5% gone) 
*The placement of samples in relation to the location of the fan inside spray coater was 
different in each case 
Eudragit 
L100-55 with 
15%TEC 
15 9.86 +/- 0.39 Almost com-
pletely dissolved 
in about 10-15 
min 
Based on the re-
lease test result in 
pH3.5, it was con-
sidered pointless to 
perform release 
test in pH5.0 
Eudragit 
L100-55 with 
5% DBS 
20 42.96 +/- 5.51 Quite stable  Partially dissolved 
(about 25% gone) 
--- --- --- --- After another 5 
hours (total = 10 
hours), not yet 
completely dis-
solved (about 30% 
gone) 
Eudragit 
L100-55 with 
5% DBS 
20 31.44 +/- 2.82 Stable  Completely dis-
solved (pH 6.0 
was used, instead 
of 5.0) after 7 
hours 
Now, the next step was to combine both chitosan and Eudragit-DBS lids together and 
perform release test using this double lids.   
5.6 pH-Sensitivity and Drug Release with Chitosan-Eudragit 
Double Lids   
The Eudragit lid formed on top of the drug-loaded MCs satisfied the hypothesis of drug 
release. However, in the actual scenario the Eudragit lid would act as an outer lid on top 
of an inner lid i.e. the chitosan lid, as previously discussed. Thus, following the investi-
gation of both lids separately, double layered lids were prepared on top of the ASSF-
loaded MCs. The double-lids-release test experiments were performed four times in 
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order to validate the results of both pH sensitivity and targeted drug delivery of the 
Eudragit and chitosan polymer lids.  
First, chitosan lid was formed over the ASSF-loaded MCs by spray coating as shown in 
Section 5.4, and SEM analysis was done in order to ensure the lid’s homogeneity, 
smoothness and completeness.  Then, the EL100-55 lid containing DBS was spray coat-
ed on top of the chitosan lid. For, Chi lid the CNTR were 60 and the avg. thickness was 
6.45 +/- 0.31 µm, whereas the CNTR for EL lid was 20 and it yield a lid thickness of 
34.2 +/- 1.8 µm. Fig. 5.26 shows the lid morphology of the double-lids formed on 
ASSF-loaded MCs.  
 
Fig. 5.26: Lid morphology analysis of chitosan lid (CNTR=60) and EL100-55 lid 
(CNTR=20) 
Following in the morphology study of the Chi-EL double-lids, the release test was run 
in 100mM phosphate buffer of pH 3.5 medium for 2 hours and then the lid morphology 
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analysis of the double-lids were performed, as presented in Fig. 5.27 and in Fig. 5.28, 
respectively.  
 
Fig. 5.27: Average % Release of ASSF in buffer pH 3.5 for 2 hours. The data represents 
an average of 4 measurements ± SD. 
 
Fig. 5.28: Lid morphology analysis of chitosan-Eudragit double-lids after the release 
test in 100mM phosphate buffer of pH 3.5 for 2 hours  
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The avg. % dissolution curve in Fig. 5.27 looks very similar to the other avg. % dissolu-
tion curves in other previous experiments performed in 100mM phosphate buffer of 
pH3.5 medium. Here, the highest average % drug release is only about 16%, which is 
very negligible.    
The lid morphology analysis in Fig. 5.28 resembles the results of earlier single lid ex-
periments, where the EL lid does not dissolve in gastric pH value. In these double-lids 
samples, the EL lid is still intact in pH3.5 medium which allows the samples to proceed 
for the next release test in pH6.0 medium.  
Following the release test in pH 3.5 medium, the Chi-EL double-lids samples were then 
ran in µDiss profiler in 100mM phosphate buffer of pH 6.0 medium for 7 hours. The 
average % release of ASSF from 4 samples is presented in Fig. 5.29 and the lid mor-
phology analysis of the double-lids afterward the release test is presented in Fig. 5.30 
below.  
 
Fig. 5.29: Average % Release of ASSF in buffer pH 6.0 for 7 hours. The data represents 
an average of 4 measurements ± SD. 
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Fig. 5.30: Lid morphology analysis of chitosan-Eudragit double-lids after the release 
test in 100mM phosphate buffer of pH 6.0 for 7 hours  
In Fig. 5.29, the highest avg. % of drug release is about 85%, which was only about 
60% in Chi single lid release experiment (Fig. 5.6) and 81% in EL single lid release 
experiment (Fig. 5.24 B) in the same pH medium as shown in the previous sections. In 
addition, another comparison can be found in the trend of the % release curves among 
these samples with three different lids (i.e. Chi lid, EL lid and Chi-EL double-lids). The 
avg. % of ASSF release starts to almost be stationary after 2 hours in Chi single lid 
samples, and after 2.5 hours in EL single lid samples; whereas the avg.  % release curve 
keeps increasing till 7 hours in samples with Chi-EL double lids. The increasing trend 
of drug release was though gradual after 2.5 hours of the drug release as shown in Fig. 
5.29. These results suggest that the Chi-EL double-lids perform much better in terms of 
higher but gradual drug release in targeted site, compared to the single lid samples.  
Following the above ASSF release test, the SEM investigation on lid morphology was 
performed as presented in Fig. 5.30. Unlike, Fig. 5.28, the porous texture of the outer lid 
(i.e. EL lid) cannot be seen in Fig. 5.30; instead a very smooth texture inner lid (i.e. Chi 
lid) has been found. It means that the EL lid is completely dissolved in pH 6.0 medium 
and the Chi lid is then exposed to the release medium. It allows the inner Chi lid to be 
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swollen and thus the ASSF to disperse through the lid into the release medium. The 
SEM images capture the scratches and some cracks on the Chi lid. These images also 
resemble the lid morphology of other similar experiments performed during this valida-
tion study. The major results of the validation experiments using Chi-EL double-lids are 
summarized below in Table 5.3. This is to be noted that some of the results were affect-
ed by unfavorable circumstances such as clogging in spray coater nozzle during chi-
tosan lid formation, swollen lid due to environmental factors e.g. humidity and air expo-
sure, and biased release curve due to broken samples during the release test. Images of 
such exceptional scenarios are shown in APPENDIX D-G.  
Table 5.3: Summary of validation experiments involved in Chi-EL double-lids  
Avg. Thickness +/- SD 
(µm) 
n=4-5 
Highest avg. 
% release of 
ASSF in pH 
3.5 
Highest avg. % 
release of 
ASSF in pH 
6.0 Chi lid EL lid 
6.45 +/- 0.31 34.2 +/- 1.8 16% 85% 
6.31 +/- 0.40 35.8 +/- 2.1 15% 84% 
6.20 +/- 0.30 31.4 +/- 2.8 16% 87% 
 
5.7 pH-Sensitivity and Drug Release Test using Adjuvant-based 
Chitosan-MPLA Lid and Eudragit Lid 
After the promising and reproducible results of the above validation study involving the 
Chi-EL double-lids samples, the adjuvant, MPLA, was incorporated to the Chi-lid using 
the polymer solution from Section 4.4.4 and spray coating method from Section 4.5.  
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Fig. 5.31: A. Lid morphology analysis of chitosan-MPLA lid (CNTR=60) and B. 1% 
EL100-55 with 5% DBS lid (CNTR=20) coated on top of Chi-MPLA lid 
Fig. 5.31 A. shows the lid morphology analysis of chi-MPLA lid spray coated on ASSF-
loaded samples and Fig. 5.31 B. represents the EL lid spray coated on top of chi-MPLA 
lid, in order to protect the chitosan-MPLA lid from dissolving in gastric pH (e.g. 
pH3.5). These newly formed adjuvant-based lid (i.e. Chi-MPLA lid) and pH-sensitive 
lid (i.e. EL lid) have an avg. thickness of 6.4 +/- 0.5 µm and 33.1 +/- 1.1 µm, respec-
tively.  
The release test results in 100mM phosphate buffer of pH 3.5 for 2 hours and of pH 6.0 
for 15 hours are presented in Fig. 5.32 A. and 5.32 B. respectively. Fig. 5.32 A. resem-
bles the earlier release test results in pH 3.5 with a negligible drug release in gastric 
medium. However, in Fig. 5.32 B., the highest % releases is about 80% on average 
which is similar to the avg. % dissolution results of the previous validation experiments 
in the pH 6.0 medium. Comparing Fig. 5.29 and Fig. 5.32 B., both of the avg. release 
curves have sharp increase till 2.5 hours and after that there is gradual increase in the % 
drug release. In Fig. 5.32 B., after 11 hours of drug release, the % release curve seems 
to be reaching stationary phase which could not be found in the Fig. 5.29 since that ex-
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periment was run for 7 hours only and till the end it had slow increase in the % release 
curve.  
 
Fig. 5.32: A. Average % Release of ASSF from Chi-MPLA & EL lids coated MCs in 
buffer pH 3.5 for 2 hour; B. Average % ASSF dissolution during the release test for 15 
hours in buffer of pH 6.0. The data represents an average of 4 measurements ± SD.  
Thus, the % drug release of ASSF from Chi-MPLA and EL (double-lids coating) coated 
MCs in both gastric and small intestinal media looks reproducible and promising in 
terms of their pH-sensitivity and targeted drug release capacity.  
82 
 
The lid morphology analysis of this double-lids samples after the release test in pH 3.5 
and in pH 6.0 media are presented in Fig. 5.33 A. and B. respectively.  
 
Fig. 5.33: Lid morphology analysis of chitosan-MPLA-EL double-lids after- A. the re-
lease test in pH 3.5 for 2 hours (Fig. 5.31 A.); B. the release test in pH 6.0 for 15 hours 
(Fig. 5.31 B.) 
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The lid morphology analysis in SEM (Fig. 5.33) after both release tests resembles that 
of the similar previous experiments in terms of lid texture and roughness. However, 
since the release experiment in pH 6.0 medium was run for 15 hours, therefore, there are 
more scars found in the lid in Fig. 5.33 B. and also, the lid looks a bit lifted in many 
places on the samples, compared to the similar double-lids release test experiment in 
Fig. 5.30 for 7 hours.  
Hence, the pH-sensitive and adjuvant-based Chi-MPLA-EL double-lids have been 
proven to be promising in terms of targeted drug delivery for oral vaccination.   
5.8 Statistical Analysis of the Effects of Polymeric Lids on Drug 
Release  
In this section, the effects of different polymeric lids on the ASSF-loaded MCs are in-
vestigated in terms of their drug release capacity at the pH value of small intestine (pH 
6.0). Five different samples i.e. i) control samples with no polymeric lid, ii) samples 
with chitosan (Chi) lid, iii) samples with Eudragit (EL) lid, iv) samples with EL + Chi 
lid and v) samples with EL+MPLA incorporated Chi lid are analyzed in Fig. 5.34.  
In this analysis, the two variables considered are the average percentage of drug release 
and the time of release in hours. The ASSF release investigation was performed at pH 
6.0 buffer medium in µDiss profiler for 7 hours.  
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Fig. 5.34: The average % release of ASSF from MCs coated with no lid, EL lid, Chi lid, 
both EL & Chi lids, and both EL & Chi-MPLA lids, respectively in pH 6.0 buffer medi-
um over 7 hours. The data represent 5 measurements (n=5) for each sample category 
+/- SD 
Fig. 5.34 shows clear difference in % release of ASSF between uncoated (without lid) 
samples and coated samples. One-way ANOVA test with 95% confidence interval was 
performed between the samples of these 5 different categories including the control 
sample. The test result (p = 0.0015) proves that there is statistically significant differ-
ence in % release of ASSF over time among the samples with different polymeric coat-
ings.  
In addition, comparing the single-coated samples (EL lid and Chi lid) and double-coated 
samples (EL lid + Chi/Chi-MPLA lid) from the above figure, the single-coated samples 
release the drug much faster than the double-coated ones. The single-coated samples 
release the drug completely by 2.5 hours and reach equilibrium, whereas the double-
coated ones need about 5-6 hours to release the drug completely. This shows that dou-
ble-coated MCs behave in line with the hypothesis that it possesses slower and more 
controlled drug dissolution capacity.  
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Furthermore, comparing the two single-coated samples, the EL-coated sample releases 
almost 60% of drug during the 1st hour of the experiment whereas the Chi-coated sam-
ple releases about 40% of the drug in the same duration. This shows that the EL lid dis-
solves much quicker than the chitosan lid because chitosan, as a coating has the proper-
ty of controlled drug release (97,98).  
One-way ANOVA test with 95% confidence level was also executed only between the 
two different double-coatings – i) EL lid + Chi lid and ii) EL lid + Chi-MPLA lid. The 
test result (p = 0.6135) asserts that there is no statistically significant difference between 
these double-coatings in terms of % release of ASSF. This shows that the incorporation 
of MPLA into chitosan lid does not affect the drug release properties of chitosan lid.   
Thus, it can be concluded that the drug release is affected by different polymeric lids 
while being released in the same medium under the same conditions.   
5.9  MPLA Detection using X-ray Photoelectron Spectroscopy 
This section discusses the results of MPLA detection by XPS where three samples were 
used. These samples were- 1) plane silicon chip 2) Chitosan lid spray coated on plane 
silicon chip and 3) Chitosan-MPLA lid spray coated on plane silicon chip. The resulted 
scanning curves and their peaks were analysed using XPS handbook. For detecting the 
chemical composition, the XPS results are presented in count/second on y-axis, over the 
binding energy (eV) on x-axis. The experimental results show that the peak for silicon is 
present only in the sample 1 where no lid was coated (Fig. 5.35). However, the XPS 
results for both chitosan and chitosan-MPLA lids look almost similar in terms of their 
chemical compositions as shown in Fig. 5.35. 
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Fig.  5.35: The chemical compositions of lid samples analysed in XPS 
The distinguishing component between chitosan and chitosan-MPLA lids was the phos-
phorous. However, likewise all techniques, the XPS has its own limit of detection which 
might be the reason why the phosphorous molecule was not found in XPS while detect-
ing chitosan-MPLA lid compositions. According to studies, depending on the element 
of detection, the required minimal concentration of the element has to be above 0.05-1.0 
atom% in order to be detected by XPS (99).  
In Fig. 5.36, it can be seen that a large molecule of MPLA contains only one phospho-
rous molecule. The chemical formula of MPLA is C96H184N3O22P and the percentage 
composition of phosphorous in MPLA is only 1.76%.  (100). 
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Fig.  5.36: The binding energy chart for phosphorous detection in XPS (left; Ref. XPS 
Handbook from Danchip); and the chemical structure of MPLA (right; (100) ) 
In addition, in this experiment, only about 0.10 mg of MPLA incorporated into chitosan 
solution was spray coated on one sample.  0.10 mg of MPLA contains only 0.00176 mg 
of phosphorous molecule, which is equivalent to 5.68*10-8 mol of phosphorous. This 
tiny amount of phosphorous would be less than the required concentration needed for 
XPS detection technique. Therefore, the due to limit of detection the phosphorous and 
thus the MPLA adjuvant could not be detected in XPS.   
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6. CONCLUSION AND FUTURE IMPLICATIONS 
This chapter concludes the thesis with some conclusive remarks. Moreover, some future 
perspectives of this study are discussed.  
6.1 Conclusion 
The thesis project exclusively focuses on the development of pH sensitive and adjuvant 
based polymeric lids of MCs for targeted delivery of oral vaccines via a mucosal route. 
The objectives of the study have been successfully achieved by establishing polymeric 
pH-sensitive and adjuvant-based double-lids that can remain intact in the gastric envi-
ronment and then release vaccine formulation at targeted site in the small intestine.  
In this study, the adjuvant MPLA has been incorporated with chitosan for forming the 
double-layered lids which is a novel achievement of this thesis project. Furthermore, all 
the necessary steps to form these double-lids have been optimized in the study. The 
production of the model drug ASSF was optimized to obtain a yield of 73.4% with in-
creased repeatability. By incorporating different plasticizers and optimizing the spray 
coating parameters, the formation of both the inner and outer lid has been optimized. 
The average thickness of the inner lid (chitosan-MPLA) and outer lid (Eudragit-DBS) 
was 6.2 +/- 0.3 µm and 31.4 +/- 2.8 µm, respectively. The lid morphology study in SEM 
proves effective formation of the lids over the drug-loaded MCs. Finally, the repetitive 
drug release experiments in different pH media validate the effectiveness of the lids to 
remain intact at gastric medium and then to dissolve followed by releasing the drug at 
intestinal medium.  
The study thus, provides a detailed analysis of the necessary variables and parameters 
along with the methods to effectively form a double-layered lid on the drug-loaded 
MCs. The comparison between the drug release percentage from the MCs with MPLA 
incorporated double lids and the double lids free of MPLA shows no statistically signif-
icant difference. This shows that the presence of MPLA does not affect the lid devel-
opment as well as the drug release. This means that the MPLA can be used in the inner 
lid to trigger the immune response in living cells without compromising the pH-
sensitivity of the double-lids. Moreover, the statistical analysis comparing the drug re-
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lease from single-coated MCs and double-coated MCs demonstrate much slower and 
more controlled release while using the double-layered lids. This further proves the ef-
fectiveness of the double-layered lids for a controlled drug release.   
6.2 Future Perspectives 
In this study, MPLA has been incorporated with chitosan for triggering the immune 
response at the drug release site. However, as this is an in vitro study, the triggering of 
immune response could not be verified. Thus, this needs to be verified in future by in 
vivo and animal studies.  
XPS analysis was performed to verify different components in the lids. Nevertheless, 
the presence of MPLA could not be detected using this technique because of the limit of 
detection of the XPS instrument. Therefore, alternative detection methods such as liquid 
chromatography-mass spectrometry (LC-MS) could be used instead to detect MPLA.  
In this study, a silicon chip accommodating 625 MCs has been used as a single sample 
while performing the drug release tests. As in the animal studies, instead of a silicon 
chip full of MCs, individual MC extracted from the chip is needed to feed the animals, 
it would be interesting to study the drug release from a single MC with the double-lids 
for replicating the actual scenario.  
In addition, the thickness of the double-lids could be optimized in future studies, so that 
for the animal studies, the extraction of each MC from the silicon chip becomes easier 
and convenient ensuring the lids remain intact. The thickness optimization study, there-
fore, should focus on two aspects- 1) the ease of microcontainer extraction and 2) the 
stability of the lids in release media. This study has further potentials to investigate the 
double-lids’ sealing using other clinically significant biocompatible polymers, along 
with incorporating antigens, such as ovalbumin, in a particulate system as for example 
the cubosomes. Therefore, the next step of this study could be the cell studies (e.g. m-
cells) and then the animal studies using the double-lids for different vaccine formula-
tions. 
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APPENDIX A: Range of furosemide standard solution’s concentration chosen to pre-
pare standard curves for the release test in µDiss profiler.  
 
Table A-1: Standard solutions for phosphate buffer pH 3.5 
STD. NO Volume of Standard 
Sol. (µl) 
Add Furosemide 
 (µl) 
Concentration  
(mg/ml) 
0 0  0 
1 10 10 0.01 
2 20 10 0.02 
3 30 10 0.03 
4 40 10 0.04 
5 60 20 0.06 
6 80 20 0.08 
7 100 20 0.1 
8 150 50 0.15 
9 200 50 0.2 
Table A-2: Standard solutions for phosphate buffer pH 5.0, and pH 6.0  
STD. NO Volume of Standard 
Sol. (µl) 
Add Furosemide 
 (µl) 
Concentration  
(mg/ml) 
0 0  0 
1 50 50 0.04975 
2 100 50 0.09901 
3 200 100 0.1961 
4 400 200 0.3846 
5 600 200 0.5660 
6 800 200 0.7407 
7 1000 200 0.9091 
8 1500 500 1.3043 
9 2000 500 1.6667 
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APPENDIX B: Some challenges with Powder Embossing method 
 
Fig. B 1: Poorly loaded MCs with ASSF using Powder Embossing method 
 
 
 
Fig. B 2: A. Wastage of drug (compressed) in powder embossing method and B. Broken 
sample due to misalignment of shadow mask. 
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APPENDIX C: Rugged shadow masks (red circles) due to overuse  
 
Fig. C: Different shadow masks (left) and Rugged shadow masks due to being used for 
a long time in embossing method (right) 
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APPENDIX D: Humidity, wet weather and rainy day seem to affect the ASSF, lids and 
thus the drug release %. 
 
 
Fig. D: A. ASSF drug is being hydrated due to humidity and exposure to air B. Swollen 
of Eudragit L100-55 (with 5% DBS) lid found after 2 hours release test in 100mM 
phosphate buffer of pH3.5 due to external humid environment 
A 
B 
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APPENDIX E: Chitosan lid formation (CNTR=60) affected by technical problem and 
environmental factors  
 
 
Fig. E 1: A. Partial clogging of spray coater’s nozzle resulted into uneven chitosan lid 
surface B. It also yields a much thinner Chi lid than usual. This chitosan lid 
(CNTR=60) is only about 4.2 +/- 2.1 µm thick, as measured by stylus profiler 
A 
B 
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Fig. E 2: A. The nozzle is properly spraying chitosan solution; B. The nozzle is partial-
ly blocked and has stopped spraying, instead drops of solution are pouring off 
 
Fig. E 3: The above Chi-lid was also affected by both humidity (top) and clogging of 
spray coating nozzle (bottom). The thickness of this lid was only 2.8 +/- 1.2 µm. 
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APPENDIX F: SEM images of Chi-EL coated double-lids reveal that the environmen-
tal factors such as humidity and air exposure negatively affected the double-lids mor-
phology.  
 
Fig. F 1: Properly coated Chi-EL double lids on top of ASSF-loaded MCs 
 
 
Fig. F 2: Lid morphology of Chi-EL coated double-lids following the release tests in 
gastric medium (pH 3.5) 
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Fig. F 3: A. Lid morphology of double-coated samples after the release test in pH6.0; 
B. Crystalline ASSF is found inside the SU8 MCs through the holes on the chitosan lid 
after the release test in pH6.0. In this experiment, the thickness of the inner lid (Chi-lid) 
was unexpectedly low due to external factors and therefore, unlike other experiments 
with double-lids samples, more holes in chitosan lid are seen in the above image.  
A. 
B. 
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APPENDIX G: Biased release curve during a release test study due to broken sample 
during the ongoing release experiment  
 
Fig. G: A. Broken drug-loaded and lid-coated sample in a µDiss vial during release 
experiment B. Broken sample resulting into unusual high drug release (red curve) com-
pared to the intact samples (in pH 3.5 medium during a trial experiment).  
A 
